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Reprogramming differentiated somatic cells to developmentally more 
potent states opens up a new era in regenerative medicine and research. In 
particular, the generation of induced pluripotent stem cells (iPSCs) which are 
expandable and pluripotent offers unprecedented opportunities for disease 
modeling, drug screening and autologous cell therapy.  
However, the lengthy preparation of fibroblasts as starting materials and 
the genomic integration of viral vectors associated with the traditional iPSC 
technology impede its wide applications in basic research and therapy. Therefore, 
identifying a more accessible source for reprogramming and development of non-
virus, non-integrating reprogramming technology is highly desired.  
Blood cells offer several advantages compared with other cell types. They 
are easy to obtain from cord blood and peripheral blood, and can expand in a 
relative short period. In this thesis, I devised several culture conditions to 
propagate different populations of blood cells and demonstrated that blood cells 
are facile for efficient reprogramming. Using the blood cells, I also tested a novel 
set of episomal vectors that can replicate as extra-chromosomes and express 
key reprogramming transgenes for iPSC generation. After one round of 
transfection, both CD34 enriched progenitor cells and the expanded monocuclear 
cells (MNCs) can be efficiently reprogrammed; numerous bona fide iPSC clones 
were generated from patients and healthy donors. Detailed studies showed these 
iPSCs were free of episomal vector integration and maintained pluripotency.  
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Complementary to the iPSC generation, I sought to reprogram human 
blood cells to clinically more relevant cell types. Lifelong blood cell generation is 
dependent on rare hematopoietic stem/progenitor cells (HSPCs) to self-renew 
and generate all blood lineages. HSPCs hold promise in clinical transplantation 
but ex vivo expansion of HSPCs is still largely unsuccessful. Based on recent 
progress in direct reprogramming, I hypothesized that HSPCs can be generated 
from differentiated blood cells. I manipulated lineage-committed blood cells with 
standard reprogramming factors and cultured the cells in conditions that favor 
HSPC expansion. Strikingly, a group of cells expressing HSPC markers emerged 
after reprogramming. In vitro characterization further proved these cells can 
differentiate into multiple blood lineages. This study has potentially wide-ranging 
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Development and Cell Differentiation  
Biological development is a dynamic process of cell growth and 
differentiation. It begins with versatile stem cells which proliferate and undergo a 
unidirectional course of differentiation that results in the acquisition of lineage 
specificity, cellular identity, unique functionality and loss of developmental 
potential. These differentiated cells become the basic units in the composition of 
multicellular organisms.  
This process was first depicted by Waddington (1957) in his epigenetic 
landscape more than half a century ago (Figure 1-1). Cell fate is determined like 
a marble rolls down from the top to the lower stable state. Taking a developing 
embryo (fertilized zygote) as an example, we can imagine it has a status 
corresponding to a marble at the crest of hill due to its highest potential to give 
rise to every cell present in the organism and generate an entire animal (Figure 
1-1). The term “totipotent” is given to describe an embryo’s ultimate 
differentiation capability. When an embryo starts to grow and divide, the progeny 
cells gradually differentiate and get distinct fates just like balls rolling down to 
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different valleys and reaching the point of lowest local elevation. The more a ball 
falls, the more a cell’s program gets fixed and loses differentiation potential.   
 
Reprogramming Cell Fate 
It was originally thought such downhill cellular differentiation was an 
irreversible process during normal development. Cells lost their plasticity forever 
once they fully differentiated. However, the seminal studies of somatic cell 
nuclear transfer (SCNT) into enucleated oocytes led by Briggs, King, Gurdon and 
Wilmut shed the light that cell fate is not unalterable after differentiation (Briggs 
and King, 1952; Gurdon et al., 1958; Wilmut et al., 1997). The cell fusion of 
pluripotent cells with differentiated cells provided additional evidence to show that 
the somatic epigenome can be reset (Cowan et al, 2005). From that time on, 
scientists realized differentiated cells didn’t bear irreversible nuclear changes and 
still kept all required genetic material capable of making an entire organism.  
In 2006, Yamanaka and his group made another big leap by showing that 
overexpression of four transcription factors can reprogram somatic cells back to 
a pluripotent state (Takahashi and Yamanaka, 2006). They used retro-viruses to 
delivery four key genes, Oct4, Sox2, Klf4 and c-Myc into mouse fibroblasts. After 
selection under embryonic stem cell (ESC) culture conditions, a cell type 
indistinguishable from ESCs in terms of morphology and property showed up. 
Yamanaka’s group termed these new cells induced pluripotent stem cells (iPSCs) 
(Figure 1-2). Like ESCs, iPSCs can self-renew and harbor the potential to 
differentiate into cell types of all three germ layers. Their pluripotency was tested 
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using mouse tetraploid complementation assays and showed mouse iPSCs can 
grow into an entire mouse (Boland et al., 2009; Kang et al., 2009). In 
Waddington’s landscape, this cellular reprogramming can be portrayed to lift a 
bottom marble to a summit state (Figure 1-1, purple outlined arrow). 
The generation of iPSCs offers unique ethical and biological advantages 
to ESCs in many aspects. First, iPSCs derivation does not involve destruction of 
human embryos, circumventing many potential moral issues. This makes cellular 
reprogramming a more attractive method to scientists and policy makers than 
nuclear reprogramming, which requires sacrifice of human embryos. In addition, 
cells used for reprogramming can be taken directly from patients. The resulting 
iPSCs are genetically identical to the original donors. Thus, cells and tissues 
derived from iPSCs transplanted to patients would not result in immune rejection. 
Although more studies are required to prove iPSCs do not elicit immune 
responses, using a patient’s own sample for reprogramming lends credit to future 
autologous cell transplant. It may also eliminate the need for immunosuppressive 
treatments.  
iPSCs also have unprecedented value for disease modeling and drug 
development (Figure 1-2). Many iPSC lines carrying different disease-related 
mutations have been reported thus far (reviewed by Cherry and Daley, 2013). 
Patient-derived iPSCs maintain the disease genotype and can be used to study 
the pathogenic phenotypes and screen drugs to cure diseases. All of these great 
discoveries made from nuclear and cellular reprogramming became important 
foundations for stem cell biology and regenerative medicine. 
3
 
Current Hurdles in iPSC Generation 
The capability to restore pluripotency from somatic cells provides hope for 
cell therapies. However, before iPSCs can be widely considered for scientific 
research and clinical treatments, several issues should be addressed, including 
cell sources for iPSC derivation, reprogramming efficiency and reprogramming 
methods. First, iPSC derivation commonly utilizes skin fibroblasts, which involves 
local anesthesia for donor skin biopsy (Figure 1-2). Such process is labor-
intensive and takes time to grow to enough cells before reprogramming can be 
conducted. In addition, human skin fibroblasts may have been exposed to 
ultraviolet irradiation and have increased risk of harboring genetic abnormalities. 
Sampling of blood is one of the least invasive but most routinely performed 
clinical procedures. A sufficient amount of blood cells can be harvested and 
expanded in short period of time. Furthermore, blood cells that are derived from 
hematopoietic stem cells (HSCs) in marrow before being released into circulation 
may be less exposed to environmental mutagens. Besides, blood such as cord 
blood with different human leukocyte antigen haplotypes has been collected by 
blood banks, which can become a source for histo-compatible iPSC generation. 
These advantages make blood an ideal cell source for iPSC derivation. 
Although reprogramming efficiency in mice has dramatically increased 
over the last few years, with some studies even showing >10% efficiency 
(Anokye-Danso et al., 2011), the successful rate of reprogramming in human 
cells remains poor. The efficiency is usually below 0.1% (Ye et al., 2012). The 
4
efficiency and fidelity of reprogramming needs to be improved in order to get 
sufficient iPSC clones from potential rare samples. In addition, initial methods 
used to generate iPSCs were viral vector-mediated (Figure 1-2). Both viral 
sequence and transgenes can permanently integrate into the genome, leading to 
potential insertional mutations and disruption of genome integrity. Besides, some 
of the transgenes used for reprogramming, like c-Myc and Klf4, are oncogenes 
and have been documented as highly related to cancer initiation (Albihn et al., 
2010; Tian et al., 2010; Rowland and Peeper, 2006). Thus, creating iPSC lines 
that are virus-free and with no transgene integration is a goal I want to achieve. 
 
Hematopoietic Stem Cells for Clinical Application and Remaining Obstacles  
The hematopoietic hierarchy has been considered the most well studied 
stem cell system in human body. It includes the most primitive blood cells called 
hematopoietic stem cells (HSCs) residing at the top of hierarchy (Figure 1-3). 
HSCs can self-renew indefinitely and have the potential to generate every 
lineage of blood cells found in the hematopoietic system. Everyday a portion of 
HSCs exit the self-renewing circuit and differentiate into multi-potent progenitors 
committed progenitor cells which are shown in the middle part (Figure 1-3).  
Following the stream of differentiation, they finally give birth to mature blood cells 
that locate at the end of the hierarchy (Figure 1-3, lower portion). Mature cells 
are terminally differentiated cells with specific functions and consist of different 
cell types, including red cells (erythrocytes), white cells, platelets, lymphoid cells, 
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etc. The whole process is tightly regulated and any tiny flaw may cause a 
detrimental effect or even threaten the growth of the entire organism. 
To date, HSC transplantation is still the only available and routinely 
performed stem cell-based therapy in clinic. This is because HSCs have the 
ability to reconstitute the whole blood system once transplanted to the recipient. 
Therefore, derivation and expansion of these valuable cells efficiently would be a 
big asset to the clinical hematology.   
Attempts to expand HSCs ex vivo have been exhaustedly investigated for 
many decades. Approaches covering from signaling pathway studies to bioactive 
compound screening have been tested, but no satisfactory results have been 
achieved yet (Blank et al., 2008; Staal and Luis, 2010; Trowbridge et al., 2006; 
Boitano et al., 2010; Takizawa, et al., 2011; Hofmeister et al., 2007). The 
expanded cells usually do not fit the qualitative and quantitative requirement for 
transplantation. The difficulty of obtaining HLA-matched HSCs for allogenic HSC 
transplantation also complicates the strategy of ex vivo expansion. 
The generation of pluripotent stem cells (PSCs) like ESCs and iPSCs 
opens a new platform to generate HSCs. PSCs are self-renewing cells and can 
be cultured without losing their pluripotency features. Many in vitro differentiation 
systems have been developed, either mediated by aggregation of PSCs into 
three-dimensional spheres called embryoid bodies (EBs) or by two-dimensional 
co-culture with stromal cells. However, the in vitro derived hematopoietic cells 
from PSCs still lack robust in vivo engraftment and repopulation activities in 
conditioned recipient mice. Taken together, it remains a large challenge to ex 
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vivo expand HSCs or differentiate PSCs to HSCs. One of the reasons is that we 
cannot recapitulate the microenvironment necessary for normal blood 
development and HSC maintenance. In addition, not all the cell types and 
interactions supporting HSC proliferation have been identified. Thus, a novel 
strategy toward generating transplantable HSCs is highly desired. 
 
Direct Reprogramming – the Concept of Dedifferentiation 
Many different kinds of animals show a certain level of regeneration 
capability to produce new cells, tissues even organs to repair old, damaged or 
lost ones (Brockes and Kumar, 2002). Two of the most well-known examples 
would be the salamander and star fish. They both can regrow a new limb when 
the original one is cut off. In planarian, this feat can be more amazing -- a single 
one can be cut into hundreds of pieces and each will grow back into a whole 
planarian.  
However, the mechanism behind natural regeneration remains poorly 
understood. It is speculated that cellular dedifferentiation could be involved in this 
process. Dedifferentiation implies that terminally differentiated cells are turning 
back to a more primitive status within their original lineage. By analogy, we can 
imagine that dedifferentiation is like pushing a marble uphill to a higher but less 
stable equilibrium (Figure 1-1, red outlined arrow). This allows cells have chance 
to replicate again before redifferentiating to substitute lost cells.   
Somatic cell nuclear transfer (nuclear reprogramming) and induced 
pluripotency (cellular reprogramming) both can be seen as ultimate forms of 
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dedifferentiation (Figure 1-1, purple outlined arrow). They dedifferentiate a 
somatic cell, which lies on the bottom of epigenetic landscape (foot of hill), back 
to the very beginning of pluripotent state (summit). By studying the cellular and 
molecular mechanisms that regulate dedifferentiation and maintain stem cells, 
we may use a dedifferentiation approach to generate valuable stem cells such as 
HSCs from differentiated cells to repair damaged cells and tissues one day.      
 
My Aims 
Based on current challenges in iPSC technology and hematopoietic stem 
cell expansion, my goals for the Ph.D. study will be to reprogram somatic cells to 
iPSCs in a safe and efficient manner. I will find feasible cell types as the starting 
material and use efficient techniques to generate high quality iPSCs. In addition, I 
will reprogram differentiated cells to clinically relevant stem cells such as HSCs. 
If successful, this work will broaden our knowledge of reprogramming and bring 
stem cells to clinic a step closer.     
 
Specific Aim 1: Human iPSC Derivation from Blood Cells by Non-
Integrating Plasmids  
Blood cells are easy to derive and have closer epigenetic signatures to 
ESCs than age-matched fibroblasts, thus I will use blood cells as the starting 
material. I will determine the efficacy of novel sets of EBNA1/OriP episomal 
vectors encoding crucial reprogramming factors to derive iPSCs. In the beginning, 
CD34+ cells that represent progenitors from cord blood will be reprogrammed, 
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and followed by adult bone marrow and peripheral blood CD34+ cells. I will also 
devise culture conditions to expand unfractionated MNCs for reprogramming. In 
aim 1, I will also investigate to derive patient-specific iPSCs from patient’s blood 
samples.  
  
Specific Aim 2: Functional Analysis of the iPSCs Derived from Human 
Blood Cells by Non-Integrating Plasmids 
In addition to standard characterization of iPSCs, it is very important to 
prove that the non-integrating technique won’t result in insertion or genome 
alteration. Several assays will be performed, including PCR and whole genome 
sequencing. It would also be interesting to test the differentiation potential of 
blood-derived iPSCs by non-integrating plasmids.    
 
Specific Aim 3: Engineering Human Induced Pluripotent Stem Cells for GFP 
and Hematopoietic Specific Reporter Systems 
Candidates of hematopoietic specific promoters/enhancers will be cloned 
to regulate GFP expression. By testing the reporter system in human iPSCs, it 
may serve as a good platform to improve hematopoietic differentiation in the 
future. 
 
Specific Aim 4: Direct Reprogramming of Human lineage Committed Blood 
Cells to Hematopoietic Stem/Progenitor Cells (HSPCs) 
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Recent studies of induced pluripotency (Buganim et al., 2013) and direct 
cell conversion (Ladewig et al., 2013) (Figure 1-1, blue outlined arrow) reshaped 
our view of cellular identity and plasticity. These findings inspired me to ask if we 
can generate clinically meaningful cells such as HSPCs via cellular 
reprogramming. Based on this notion, I would like to directly reprogram lineage 
committed blood cells not all the way back to the pluripotent state, but to guide 
them to a hematopoietic primitive state. The standard reprogramming factors will 
be used to reprogram human lineage committed blood cells, and reprogrammed 
cells are going to be cultured in optimized HSPC culture condition for potential 
HSPC generation. This process can also be illustrated as “dedifferentiation” 















Figure 1-1. Waddington’s epigenetic landscape to illustrate the
biological development and cell fate conversion. Differentiating cells
are depicted as a ball rolling down a hill. Each concave represents a
stable cell lineage. The height of a cell positively reflects the
differentiation potential. Arrows are used to depict how cells can convert
to other cell fates. The figure is reproduced from the original text by
Waddington. Abbreviations: ESCs, embryonic stem cells; iPSCs, induced














• Lengthy preparation of fibroblasts
• No easy accessible source
• Low reprogramming efficiency
• Insertional oncogenic risk
• Disruption of genome integrity
• Poor differentiation protocol
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Figure 1-2. The concept of iPSCs for regenerative medicine
applications and current hurdles in iPSC generation. iPSCs from

























































Figure 1-3. The human hematopoietic system. Hematopoietic stem
cells reside at the top of hierarchy which can self-renew and give rise to
multiple lineages of blood progenitors and mature blood cells.
Abbreviations: MPP, multi-potent progenitor; CMP, common myeloid
progenitor; CLP, common lymphoid progenitor; MEP, Megakaryocyte
/erythrocyte progenitor; GMP, granulocyte/macrophage progenitor.
15
Chapter 2 





Human induced pluripotent stem cells (iPSCs) that morphologically and 
functionally resemble human embryonic stem cells (ESCs) have been generated 
from a wide spectrum of somatic cell types by viral vectors expressing defined 
reprogramming factors since 2007 (Takahashi et al., 2007; Yu et al., 2007; Park 
et al., 2008). Fibroblastic cells from a skin biopsy are one of most common 
sources for iPSC generation. But the lengthy and cumbersome culture prior to 
reprogramming invoked researchers to find a better source for reprogramming 
(Figure 1-2).     
To identify accessible and permissive human cell types for efficient 
derivation of iPSCs, our lab has investigated epigenetic and gene expression 
signatures of multiple postnatal tissue types. Our analysis revealed that blood 
cells display unique signatures that are closer to iPSCs and ESCs than age-
matched fibroblastic cells to iPSCs/ESCs, making blood an attractive choice for 
iPSC derivation (Figure 2-1)(Chou et al., 2011). Indeed, blood sampling can 
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acquire sufficient cell number instantly and has been routinely performed in 
clinical settings.  
Of many blood cell types that can be potential candidates for iPSC 
generation, cord blood CD34+ cells have several advantages than other blood 
cells. Cord blood has an abundance of CD34+ cells, which are enriched for 
hematopoietic stem cells (HSCs) and have higher proliferation potential than 
CD34+ cells from other blood origins. Cord blood cells also have been widely 
collected in hospitals and stored in many blood banks and can be acquired. The 
huge reservoir of cord blood is suitable for basic research or future therapeutic 
usage. In addition, blood cells from newborn babies have limited, if not nil, 
exposure to environmental mutagens and minimize the risk of genetic damage. 
All of these reasons make cord blood an excellent cell type for reprogramming. 
CD34+ cells isolated from adult bone marrow which has been investigated 
extensively over many years is one of the most common methods to purify 
HSPCs from human (reviewed by Doulatov et al., 2012). In recent years, 
mobilized peripheral blood (mPB) has become another major source of adult 
CD34+ cells. This is owing to the discovery that peripheral blood of mice treated 
with repeated G-CSF drastically increased the colony-forming unit in spleen pool 
(Molineux et al., 1990). Besides, collecting mPB can bypass the invasive 
procedure to harvest bone marrow cells. In clinical transplantation, mobilized 
peripheral CD34+ blood cells have a trend to replace bone marrow CD34+ cells. 
And one unique advantage of BM and mPB compared to CB is that we can 
harvest BM or mPB cells from patients who have genetic mutations. The iPSCs 
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derived directly from patients provide a valuable tool not only in disease modeling, 
but also in drug discovery, toxicology and even stem cell therapies where 
immune rejection is no longer a concern. Therefore, it is important to reprogram 
not only cord blood but also many other types of blood cells in an efficient 
manner.  
However, even in cord blood, the CD34+ cells are very rare and isolation 
of the CD34+ cells is cumbersome. For certain diseases like aplastic anemia in 
which patients have a shortage of CD34+ blood cells, isolating CD34+ cells 
would be quite challenging. Therefore, several groups are generating human 
iPSCs from “unfractionated” blood mononuclear cells (MNCs) (Kunisato et al., 
2010; Brown et al., 2010; Seki et al., 2010; Loh et al., 2010; Staerk et al., 2010). 
These studies involved a long cell culture to activate T cells which are most 
abundant in peripheral (PB) MNCs into a proliferating state. T cells were easily 
expanded and infected by viral vectors under these culture conditions. But, 
detailed characterization revealed that all or the vast majority of the derived 
iPSCs in each of the 5 studies contain somatic V(D)J DNA rearrangements at the 
T cell receptor (TCR) loci. It is unclear presently, whether the preexisting 
genomic rearrangement in human T cell-derived iPSCs will affect iPSC 
differentiation to T and non-T cell lineages (Yamanaka, 2010; Serwold et al., 
2007), and whether T cell-derived iPSCs may form T cell lymphomas at an 
unexpectedly high rate as observed with reprogrammed mouse T cells  (Serwold 
et al., 2010). Therefore, developing a feasible method to skip CD34+ cell 
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purification and expand blood cells to non-T cell lineage would be a great benefit 
for iPSC derivation. 
An equally critical issue in human iPSC generation is to find an 
appropriate system to introduce reprogramming factors. Methods of iPSC 
derivation without altering the genome are preferred, ideally by a virus-free 
approach. Recently, several virus-free and integration-free methods were 
reported, which generated mouse and human iPSCs by using purified proteins, 
mRNAs as well as plasmids (Okita et al., 2008; Zhou et al., 2009; Kim et al., 
2009; Jia et al., 2010; Warren et al., 2010; Yu et al., 2009; Marchetto et al., 2009). 
However, most of these published studies using proteins or mRNAs needed 
serial delivery (up to 17 times) of multiple reprogramming molecules to targeted 
adherent cells. Two groups have used plasmid-based episomal vectors to derive 
iPSCs from human neonatal fibroblasts and fetal neural progenitor cells (Yu et al., 
2009; Marchetto et al., 2009). This is based on a well-established technology that 
inclusion of the EBNA1 gene and the OriP DNA sequence from the Epstein-Barr 
virus enables a plasmid, after one-time DNA transfection, to replicate in many 
types of primate cells as a circular episome (Lindner and Sugden, 2007). 
However, the reported efficiency of episomal vector-mediated reprogramming 
was very low (~3-6 iPSC clones per 106 neonatal human fibroblasts) even when 
the best combination of 3 ENBA1/OriP plasmids expressing 7 genes was used in 
DNA transfection (Yu et al., 2009). For cell therapy development and disease 
modeling, it is necessary to develop more efficient methods to generate 
integration-free and virus-free human iPSCs from adult somatic cells that tend to 
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be more refractory to reprogramming as compared to fetal/neonatal cells. 
Therefore, an improved EBNA1/OriP episomal vector system would be required 
to reprogram adult and neonatal somatic cells efficiently.   
 
Approach  
Finding a suitable starting cell population and a non-integrating method 
will be the key to derive high quality iPSCs. Our lab has previously reported that 
CB CD34+ cells can be fully reprogrammed by retroviral vectors (Ye et al., 2009). 
Base on their easy acquisition and high growth potential, I will start from human 
cord blood CD34+ cells and expand cells in a chemically-defined culture 
condition, which is feeder cell free and serum free, to generate sufficient 
proliferating cells. In the same time, inspired by the potential advantage of using 
the episomal plasmid in previous studies, my colleague and I cloned essential 
reprogramming genes, Oct4, Sox2, Klf4, c-Myc and Lin28 into a single episomal 
vector through linkage of distinct self-cleaving 2A peptides (accredited to P. Mali). 
The vector consists of EBNA1 gene and an OriP DNA sequence both originally 
from Epstein-Barr virus. EBNA1 protein binding to OriP sequence can boost 
vector replication and sustain vector as an episomal form during cell division, 
thus enhance the expression of transgenes. The easy-handling property of 
episomal-based system encourages me to explore how an efficient episomal 
vector can reprogram human cord blood CD34+ cells.  
I will test if this novel episomal vector can also reprogram other CD34+ 
cells such as from BM and mPB. If successful, it would set up a solid foundation 
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to reprogram blood harvested from general populations and patients. Just in case 
I have to cope with some cell types that are more refractory to reprogramming, I 
also seek to refine methods that can enhance overall reprogramming efficiency. 
Factors and small molecules that have been shown to improve reprogramming 
will be also utilized. 
CD34+ cell isolation is a time-consuming process and may have some 
detrimental effects on donors. Therefore, I will try to reprogram MNCs either 
without CD34 purification or from CD34 depleted cells. Instead of growing MNCs 
to lymphoid lineage where resulting somatic rearrangement may constrain iPSCs’ 
capability to a full spectrum differentiation, I will culture cells in a condition that 
favors erythrocyte/megakaryocyte growth from unfractionated MNCs. Hopefully 
erythroblast progenitor cells can be stimulated and maintained in a high 
proliferative rate which is prerequisite for successful reprogramming (Ruiz et al., 
2011). Lastly, blood cells from a patient will be also tested to derive patient-
specific iPSCs.  
 
Results 
Expanding Cord Blood CD34 Positive Population in Serum-Free Media 
Cord blood (CB) cells with or without CD34 pre-fractionation were 
acquired from AllCells, Ltd. CB CD34+ cells after serum-free media (SFM) and 
supplemental cytokines culture can expand to 3-5 fold. Prolonged culture proved 
cells were in a rapidly growing state. It has been documented a high proliferate 
rate is crucial for efficient reprogramming (Ruiz et al., 2011). The majority of cells 
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maintain CD45+ and CD34+ markers (data not shown); CD45 is a pan-
hematopoietic cell marker while CD34 marker is an important indicator of HSPCs. 
In addition, colony forming units (CFU) assay demonstrated cells after SFM 
expansion still possessed the property to form colonies with different types 
(Figure 2-2). Taken together, these data indicated that CB CD34+ cells after 
expansion are in an appropriate condition for efficient reprogramming.    
 
Reprogramming Human Cord Blood CD34+ Cells by Episomal Vectors 
I next tested a novel set of ENBA1/OriP plasmids constructed for 
reprogramming cultured CB CD34+ cells, which have the most favorable 
epigenetic/gene expression signatures and proliferative capacity as compared to 
adult CD34+ cells or fibroblasts/MSCs (Chou et al., 2011). In the first 
EBNA1/OriP plasmid construct (termed pEB-C5), 5 reprogramming factors from 
mouse origin: Oct4 (also known as pou5f1), Sox2, Klf4, c-Myc and Lin28, are 
expressed as a single polycistronic unit through self-cleaving peptides linking 
(Figure 2-3A). In the second set of EBNA1/OriP plasmids, SV40 Large T antigen 
(pEB-Tg) was constructed to test additive effect of reprogramming, while GFP 
was used as an efficiency control (pEB-GFP) (Figure 2-3B). To test the efficacy 
of novel pEB-C5 and -Tg, I compared them with the combination of 3 vectors 
used in previous studies (combination #6) (Yu et al., 2009). After expansion (~5-
fold) with cytokines for 4 days, CB CD34+ cells were transfected once and then 
cultured on MEF feeders following the standard protocol for deriving human 
iPSCs (Ye et al., 2009; Mali et al., 2010) (Figure 2-3C). Two small molecules, 
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sodium butyrate (NaB) and valproic acid (VPA) that have been reported to 
improve reprogramming were added individually. Strikingly, expanded CB CD34+ 
cells were very amenable to reprogramming after episomal plasmid nucleofection. 
The emergence of iPSC-like colonies came up as early as day 5-6 post 
nucleofection (Figure 2-4A, arrow) and hundreds of colonies showed up in next 
2 weeks. 
Previous studies showed that the acquisition of cell surface expression of 
TRA-1-60/TRA-1-81 is a better marker for monitoring full reprogramming of 
human somatic cells (Mali et al., 2010; Chan et al., 2009; Lowry et al., 2008). I 
performed TRA-1-60 live staining of whole cultures at day 14 and numerated 
both TRA-1-60 positive (+) and negative (-) colonies (Figure 2-4B, Figure 2-5A, 
B). Live-staining of TRA-1-60 suggested that most of emerged colonies were 
bona fide iPSC lines (Figure 2-4B, C). Our 2-plasmid combination (C5+Tg) 
generated similar numbers of TRA-1-60+ colonies (Figure 2-5A), but their 
percentages among total colonies were much higher than combination #6 
(Figure 2-5B). Various TRA-1-60 negative colonies generated by combination #6 
resemble mere transformed cells rather than fully reprogrammed clones (Figure 
2-4D, E). This data indicates C5-based reprogramming is competitive to 
combination #6 in terms of efficiency and can be a more reliable method to 
derive true iPSCs. 
 
Reprogramming Human Cord Blood CD34+ Cells by C5 with p53shRNA or 
NANOG 
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I would like to test whether I can replace Tg by either NANOG or other 
factors. Therefore, a transient vector expressing human NANOG was generated. 
In another set of EBNA1/OriP constructs, a small hairpin RNA targeting p53 
(termed p53shRNA) was cloned to confer p53 interference effect (Figure 2-3B). 
The purpose is to test if p53 silencing or NANOG expression can deliver the 
same result as Tg expression. I also addressed if Tg can be omitted completely. 
The stimulatory effect of CB CD34+ cell reprogramming by the second vector 
over pEB-C5 alone was the greatest by Tg followed by p53shRNA, and minimal 
by NANOG (Figure 2-6A). The pEB-C5 plasmid alone was sufficient to generate 
about 50 TRA-1-60+ colonies from 106 nucleofected cells (from approximately 
0.2x106 original CD34+ cells (Figure 2-6A). This data showed Tg is not essential. 
In the presence of the second plasmid, the efficiency can be enhanced to close 
roughly 100 TRA-1-60+ colonies from 106 nucleofected cells.  
 
Sodium Butyrate Can Enhance Reprogramming Efficiency   
I observed that sodium butyrate (NaB), a nutritional supplement and 
histone deacetylase (HDAC) inhibitor that stimulates reprogramming of human 
fibroblastic cells (Mali et al., 2010), also consistently enhanced the number and 
percentage of TRA-1-60+ colonies by either vector combination (Figure 2-5 and 
2-6 A, B). In the presence of NaB at millimolar level during the reprogramming 
(day 3-14), about 160 TRA-1-60+ colonies were generated in C5 alone condition, 
reflecting more than 3-fold increase. Moreover, the percentage of TRA-1-60+ 
colonies also raised to 50% of the total colonies formed (Figure 2-6B). This 
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result showed the advantage of including NaB as a supplement to boost 
reprogramming.      
 
Characterization of iPSCs from CB CD34+ Cells by Episomal Vectors 
After TRA-1-60 live staining, I picked individual iPSC-like colonies derived 
by transfection with either pEB-C5 alone (C), pEB-C5 + pEB-Tg (CT) or CT in the 
presence of NaB (CTN). I examined at least two CB-derived clones from each 
category by standard assays. Undifferentiated phenotypes of one representative 
clone, C7, is shown (Figure 2-7A), and additional clones CTN4 is shown (Figure 
2-9A). I found that 5 of 6 clones derived with pEB-C5 + pEB-Tg vectors have a 
normal karyotype, including C7, CN1, CT5 and CTN4 (Figure 2-7B and Figure 
2-9B). To further analyze iPSCs derived with transient expression of Tg, I used 
genome-wide SNP analysis to examine the similarity of the CT5 and CTN4 
genome to that of primary CB CD34- cells from the same CB donor. The 
genome-wide data (covering more than106 SNPs) indicated that CT5 and CTN4 
iPSCs are essentially identical to CD34- cells of the CB donor and that 
reprogramming by the episomal vectors did not cause any detectable alterations 
in the genome (see Materials and Methods). Equally important, CT5 and CTN4 
iPSCs were pluripotent as validated by both in vitro and in vivo differentiation 
assays (Figure 2-10). Similarly, the iPSC clones derived by the single C5 vector 
from the same donor (CN1) and a different donor (C7) were also pluripotent 
(Figure 2-8).  
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Reprogramming Adult Hematopoietic CD34+ Cells by 1-2 Episomal Vectors 
I also acquired adult BM CD34+ cells from AllCells, and tested with 1 or 2 
EBNA1/OriP plasmids (Figure 2-11). Cells were cultured under serum-free and 
feeder cell-free condition. After 4 days of expansion, 106 cultured cells were 
nucleofected by C5 alone, C5 + Tg or C5 + p53shRNA. The iPSC-like TRA-1-60+ 
colonies emerged between day 9 and day 11, about 3-4 days later than those 
from CB CD34+ cells. I found the efficiency of reprogramming adult CD34+ cells 
was 50-fold lower than CB CD34+ cells per 106 cells transfected by the same 
vector sets, although sufficient numbers of iPSC colonies formed (Figure 2-11A). 
Adding a second EBNA1/OriP vector expressing Tg or shRNA targeting p53 
increased the efficiency by ~5-fold.  
Since BM aspiration is a complicated process, I next tested CD34+ cells 
from a more accessible adult source--mobilized peripheral blood (mPB). Again, 
the same 3 sets of episomal plasmid combinations were used. I found in general 
the mPB efficiency for iPSCs is similar to BM cells. With the help from Tg, the 
colony numbers were increased. Meanwhile, p53shRNA was close to Tg to 
derive iPSCs. One clone from BM CD34+ cells (BC1) was further characterized 
after 5-12 passages. This BC1 clone reprogrammed by the single pEB-C5 vector 
was picked, expanded and characterized as before. BC1 showed undifferentiated 
phenotypes (Figure 2-12A), had normal karyotype (Figure 2-12B), and was 
pluripotent by in vitro (Figure 2-13A) and in vivo (Figure 2-13B) differentiation 
assays. These data suggested that although in a low efficiency manner, episomal 
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plasmids still can reprogram adult CD34+ cells and generate reasonable iPS 
colonies.   
 
Reprogramming Unfractionated Cord Blood Mononuclear Cells by 
Episomal Vectors after Stimulation by Cell Culture 
From the view to simplify the process of iPSC derivation, circumvent the 
need of fractionation or specific cell type purification is necessary. Thus I 
attempted to reprogram unfractionated blood MNCs without CD34 purification by 
the improved episomal vectors. Uncultured or cultured MNCs under the CD34+ 
cell culture condition did not survive well before or after nucleofection, resulting in 
zero iPSC colonies per five million MNCs (data not shown). I tested various 
culture conditions that would stimulate myeloid-erythroid proliferation from MNCs, 
and avoided the standard protocols expanding T and/or B cells that contain 
V(D)J DNA rearrangements. V(D)J DNA rearrangement indicates some 
nucleotides in the genome have been trimmed and results in altered genome. I 
chose a condition that stimulates erythroblast proliferation (van den Akker et al., 
2010) for the following 2 reasons. 1) I observed net gains of cell numbers after 
culture: 2.5 fold by day 8 for CB MNCs and 1.5 fold by day 10-14 for PB MNCs, 
despite a reduction in the first 2-4 days (Figure 2-14A). 2) The expanded cells 
contained very few T or B cells compared to input MNCs (Figure 2-14B, C). 
Nearly all the expanded cells expressed pan-hematopoietic marker CD45 
(Figure 2-15A), and many expressed CD235a+ erythroid phenotypes (Figure 2-
15A). There were only minimal CD34+ cells (Figure 2-15A). Expanded cells also 
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showed erythroblast morphology at day 8-9 (Figure 2-15B), and were enriched 
for colony-forming erythroid progenitor cells (data not shown). The data 
suggested that the resulting cells after expansion are enriched for highly 
proliferative erythroblasts as previously reported (van den Akker et al., 2010).  
I devised a condition to efficiently transfect expanded cells with favorable 
profiles. Two million cells were transfected one-time by nucleofection with the 
same one to three EBNA1/OriP episomal vectors, and followed by identical 
reprogramming protocol as before (Figure 2-3C). The 8-day-cultured CB MNCs 
after nucleofection can generate TRA-1-60+ iPSC-like colonies very efficiently 
(Figure 2-16A). Although variations of different CB MNC preparations existed, 
the overall reprogramming efficiency is very high: 460 and 160 TRA-1-60+ 
colonies formed by day 14 per 106 transfected MNCs by the single pEBC5 
episomal vector in the presence of NaB. The stimulatory effect of Tg or NaB is 
minimal for the cultured CB MNCs (Figure 2-16A). However, in the presence of 
NaB, I can always observe higher percentage of TRA-1-60+ colonies over total 
emerged colonies, indicating a low incidence of transformed cells (Figure 2-16B). 
 
Reprogramming Unfractionated Adult Blood Mononuclear Cells by 
Episomal Vectors after Stimulation by Cell Culture 
I also tested to culture adult unfractionated peripheral blood (PB) MNC for 
erythroid expansion. Again, cell number decreased in the beginning of culture, 
but gradually to rebound around one week (day 9, Figure 2-17A). By day 15 I got 
7.2 million cells which was more than initial input cell number. I reprogrammed 
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expanded cells by C5 alone or together with Tg, all were in the presence of NaB. 
Although the efficiency is much lower than that of CB MNCs, I still derived a 
reasonable number of iPSC colonies from 2X106 cultured MNCs (Figure 2-17B). 
If Tg was utilized, I can generate more iPSC lines. Similar to adult PB CD34+ 
cells, PB MNC reprogramming is more dependent than CB MNCs on NaB 
stimulation. Adding pEB-Tg further increases the efficiency by roughly 3-fold, 
resulting in 2 to 37 iPSCs per 2 × 106 cultured MNCs. I further characterized the 
iPSC lines derived from cultured adult PB MNCs. Pluripotency staining of one 
expanded iPSC line, PE2, was shown (Figure 2-17C). Thus, my method is 
adequate for iPSC derivation from less than 1 ml of PB.  
 
Patient-Specific iPSC Derivation from Unfractionated Peripheral Blood 
Mononuclear Cells 
To test the idea of establishing iPSCs from a patient, I harvested PB 
MNCs from a patient with HIF2a gain-of-function mutation. In adult mice, HIF-2α 
gene plays a key role in regulating erythropoietin production and erythropoiesis 
(Semenza, 2009). This patient’s red blood cells are very sensitive to 
erythropoietin, indicating this mutation is relevant to hematopoiesis (Percy et al., 
2008a; Percy et al., 2008b; Furlow et al., 2009). CD34 positive and negative 
populations were separated by MACS CD34+ cell kit. The CD34+ population was 
reprogrammed by standard OSKM retrovirus in early days before episomal 
plasmid had been developed. Figure 2-18A showed the pluripotency staining 
and normal karyotyping of one iPSC line. The CD34- counterpart was expanded 
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under our erythroid culture condition. After C5 + Tg reprogramming, I derived 
average 37 iPS clones from 2 million starting cells. Genomic DNA was extracted 
and sent for sequencing and confirmed the existence of mutation (Figure 2-18B). 
One HIF2a-mutation iPSC line was characterized, including in vitro and in vivo 
differentiation shown in Figure 2-19. Therefore, this is proof-of-principle that 
patient-specific iPSCs can be readily derived using retroviral vector or non-
integrating plasmid. The iPSC line carrying the disease genotype would be ideal 
for disease modeling.  
  
PCR Analysis to Confirm the Authentic Origins of iPSC Lines 
To confirm the relationship between the starting cell population and 
derived iPSCs, genomic DNAs were isolated from various iPSC lines and their 
parental cells such as cord blood (CB), bone marrow (BM) CD34+ cells and 
MSCs, and adult peripheral blood (PB) mononuclear cells (MNCs). They were 
used as templates for detection of variable regions (in size) in the genome by 
PCR using two sets of specific primers. Based on the identical size of bands and 




The efficient reprogramming is largely dependent on the intrinsic property 
of starting cells. In this part of research, I found human cord blood CD34+ cells 
were an easily accessible and amenable cell type for reprogramming. They can 
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be propagated in a serum- and feeder-free conditions and reach sufficient cell 
number in a short time of culture for subsequent experiments. 
To focus on generating integration-free iPSCs, I employed a novel 
episomal vector system to transfect briefly-cultured CB CD34+ cells. The first 
iPSC-like colony can show up as early as day 6 post-transfection, which is much 
faster than traditional virus-mediated reprogramming. The overall reprogramming 
efficiency was also high, making it easy to pick up enough clones for detailed 
studies. Notably, although our novel episomal vector system generated similar 
iPSC colony numbers as previously reported episomal vectors did (Yu et al., 
2009), most emerged colonies in our system were TRA-1-60 positive. In contrast, 
colonies derived by combo#6 (Figure 2-5B) showed a significant portion of TRA-
1-60 negative. It suggests that my system is much more efficient to confer full 
reprogramming and facilitating the efficient isolation of the desired TRA-1-60+ 
colonies. 
In line with our previous study, adding NaB can enhance the efficiency of 
iPSC derivation for either fibroblasts or blood cells. Adding NaB continuously 
during the reprogramming did not negatively affect the derivation of iPSCs. This 
data supports that NaB could be included in the standard procedure.  
Transient expression of a second vector (pEB-Tg) or shRNA targeting p53 
did not show stimulatory effect, although Tg stimulation and p53 inhibition on 
reprogramming were observed by several groups using different vectors and 
somatic cell types (Yu et al., 2009; Mali et al., 2008; Zhao et al., 2008; 
Krizhanovsky and Lowe, 2009). This could be due to the high reprogramming 
31
efficiency in CB CD34+ cells. Transient expression of Tg by episomal vectors did 
not necessarily alter karyotypes of the derived iPSCs (Yu et al., 2009; Chou et al., 
2011), hence pEB-Tg may play a more important role if refractory cell types are 
going to be reprogrammed. Taken together, my platform is more flexible if one 
needs to omit or replace Tg with other factors for mechanistic investigations. 
This episomal vector system, together with optimized cell culture 
conditions, allows us to efficiently generate virus-free human iPSCs from blood 
MNCs isolated from a few milliliters of blood after suspension cultures for 8-9 
days. When further enhancement is needed for other cell types, or patient’s 
blood MNCs that are more refractory to reprogramming by the current episomal 
vectors, I can easily add additional reprogramming genes over the 5-6 
transgenes I used. Since I can deliver multiple (at least 8) genes from a single 
EBNA1/OriP plasmid for simultaneous and transient expression, it is no longer 
critical to reduce the numbers of reprogramming factors used. Obviously, small 
numbers of vectors (1-2) are preferred to ensure the terminal loss of episomal 




Figure 2-1. Global epigenetic signatures and relatedness of human
ESC lines, iPSC lines and their parental somatic cells. A dendrogram
plot using Euclidean distances and average linkage based on DNA
methylation at 26 424 autosomal loci in the Infinium Methylation27 platform,
to analyze promoter DNA methylation genome-wide. 11 hESCs (passages
30-80) and 20 iPSCs derived from various somatic cell types (passage 5-15)
that have a normal karyotype and validated pluripotency were analyzed.
Parental cell types used for reprogramming include cultured CD34+ cells
from cord blood (CB), adult peripheral blood (PB) and adult bone marrow
(BM), CB and PB mononuclear cells (MNCs) before (D0) and after culture
(D8), 4 types of adult BM stromal cells (MSC-BM, MSCs and BASC) and
IMR90 fetal fibroblasts, neonatal cord-derived endothelial cells (CD34+)
such as HUVEC and CB-derived endothelial progenitor cells (CB-EPCs).
The clustering confirms that the 20 validated iPSC lines derived from various
somatic cell sources are highly similar to ESCs, but distinct from their
parental cells. DNA methylation patterns in human blood cells are more
similar to ESC/iPSC group as compared to age-matched non-hematopoietic
cells. Based on a two-sample t-test with unequal variances, we confirmed
that the different mean distance corresponding to the indicated nodes a and




































Figure 2-2. Characterization of expanded cord blood CD34+ cells.
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Figure 2-3. Diagrams of novel episomal vectors used in this study, based
on an EBNA1/OriP-containing plasmid. (A) A reprogramming vector
expressing Oct4, Sox2, Klf4, c-Myc and Lin28 (OSKML) under the control of a
chimeric promoter CAG. The plasmid pEB-C5 is also abbreviated later as C5.
(B) Two supplementary episomal vectors expressing SV40 viral large T
antigen (Tg) or an shRNA knocking down p53. In some experiments, pEB-
GFP (under the control of the CMV promoter) was used as a vector control,
see details in Methods. (C) A procedure for reprogramming and identifying
iPSC-like cells. Purified CD34+ cells were expanded and primed for 4 days,
and then nucleofected once by 1 or up to 3 plasmids (a total of 10 g DNA) at
day 0. Transfected cells were cultured for 2 more days before transferring
onto 6-wells plated with mouse embryonic fibroblast (MEF) feeder cells. At
day 3, the ESC culture medium was used in the presence or absence of
sodium butyrate (NaB, 0.25 mM) or valproic acid (VPA, 0.5 mM). After day 9
when the original MEF feeder cells deteriorated, fresh MEF conditioned
medium (CM) was used to substitute plain ESC medium. Starting at day 10,
live staining for TRA-1-60 cell surface marker, which is expressed in human
ESCs and bona fide iPSCs, could be performed every other day. Typically,
we performed TRA-1-60 live staining at day 14, numerated colonies of both






Figure 2-4. Morphology of iPSC-like colonies. (A) Promising iPSC-like
colonies from CB CD34+ cell reprogramming can emerge as early as day 6
post episomal plasmid nucleofection, blue arrow. Phase and fluorescence
images of a colony after TRA-1-60+ live staining 14 days after one-time
nucleofection of episomal plasmid (B) (C) . Nucleofection by the
combination #6 which has 3 episomal vectors (Yu et al., 2009) showed
partially- and fully- reprogrammed colonies, blue arrow head and arrow






































































Combo #6             C5 + Tg GFP + Tg
40
Figure 2-5. Comparison of synergy of pEB-C5 and pEB-Tg episomal
plasmids with the combination #6 for cord blood (CB) CD34+ cell
reprogramming. (A) Estimating reprogramming efficiency by measuring
numbers of TRA-1-60+ and iPSC-like colonies at day 14 per 106
nucleofected CD34+ cells. Thomson/Yu combination #6 which contains 3
plasmids expressing 7 genes was compared to the C5+Tg vector
combination. Sodium butyrate (NaB) and valproic acid (VPA) were used to
test individual additive effect, 0.25mM and 0.5mM respectively. A pEB-GFP
(GFP) was used as a negative control for C5. The percentages of TRA-1-
60+ colonies among the total emerged colonies were also plotted (B). Data




























































Figure 2-6. Reprogramming efficiency of cord blood (CB) CD34+ cells
by various combinations of EBNA1/OriP epiosmal or transient
vectors. (A) pEB-C5 (C5) + pEB-Tg (Tg), C5 + pEB-p53shRNA, C5 +
NANOG or C5 alone were compared in parallel. The efficiency was
measured at day 14 as numbers of TRA-1-60+and iPSC-like colonies per
106 nucleofected cells. Sodium butyrate (NaB) was used to test individual
additive effect, 0.25mM. (B) The percentage of TRA-1-60+ colonies among
the total colonies were also plotted. Data were plotted as mean +/-SEM
(n=3). Discrete TRA-1-60+ colonies with the best iPSC-like morphology
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Figure 2-7. Characterization of iPSC lines C7 and CN1 derived from CB
CD34+ cells by the single pEB-C5 plasmid. (A) Representative images of
staining of undifferentiated C7 iPSCs after expansion (more than 5
passages) for markers associated with pluripotency. Upper row for nucleus
staining of OCT4 and NANOG. Lower row for surface staining of SSEA4
and TRA-1-60. Immuno-fluorescence staining with specific antibodies
followed by Alexa555-conjugated secondary antibodies. Scale bar: 100μm
throughout. (B) Normal karyotypes of C7 and an additional line CN1at






















Figure 2-8. Pluripotency staining of iPSC line C7 and in vitro and in
vivo differentiation assay. (A) The C7 iPSCs is positive for alkaline
phosphatase (AP) histo-chemical staining, left. (A) right and (B), C7 iPSCs
display normal in vitro differentiation pluripotency as assayed by embryoid
body (EB) formation. Eight days after culture in suspension, cystic EBs
were formed and then allowed to adhere for further differentiation. Then the
whole culture was stained by monoclonal antibodies recognizing various
germ layers including those from ectoderm (β3-tubulin), mesoderm
(smooth muscle actin) and endoderm (alpha-fetal protein or AFP). (C) (D)
In vivo differentiation assay of C7 iPSCs by teratoma formation. The cystic
teratoma-like tumors were excised from animals and sectioned. H & E
stained sections were examined. Both low (upper left, 10X) and high
(remaining, 20x) magnification images of multiple sections were shown.
Various cell types such as neural rosettes (ectoderm) (C right), cartilage
(mesoderm) (D left) and glandular structures (endoderm, yellow arrow) (D









Figure 2-9. Characterization of an additional iPSC line CTN4 derived
from CB CD34+ cells by pEB-C5 and pEB-Tg plasmids in the presence
of sodium butyrate (NaB). (A) Staining of undifferentiated CTN4 iPSCs
after expansion (more than 5 passages) for markers associated with
pluripotency. Upper row for nucleus staining of OCT4 and NANOG. Lower
row for surface staining of SSEA4 and TRA-1-60. Immuno-fluorescence
staining with specific antibodies followed by Alexa555-conjugated
secondary antibodies. Scale bar: 100μm throughout. (B) Karyotyping of




















Figure 2-10. Pluripotency assay of iPSC line CTN4 derived from CB
CD34+ cells reprogrammed by pEB-C5 and pEB-Tg plasmids in the
presence of sodium butyrate (NaB). (A) (B) In vitro differentiation
assay by embryoid body (EB) formation and differentiation. Various cell
types derived from ectoderm (β3-tubulin), mesoderm (smooth muscle
actin) and endoderm (alpha-fetal protein or AFP) were found. Scale bar:
100 μm. (C) (D) In vivo differentiation of CTN4 assayed by teratoma
formation. Low magnitude of teratoma were shown in (C left). The
presence of various cell types derived from all the 3 embryonic germ
layers were shown: neural rosette (ectoderm) (C right), adipose
(mesoderm) (D left), and grandular tissues (endoderm, yellow arrow) (D
right), in representative images of H & E stained sections. (C left), low
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Figure 2-11. Reprogramming of human adult hematopoietic CD34+
cells. Reprogramming efficiency of bone marrow (BM, A) or of adult
mobilized peripheral blood (mPB, B) CD34+ cells by various plasmid
combinations in the presence of NaB, as conducted before. Numbers of
TRA-1-60+, iPSC-like colonies were numerated (mean +/– SEM) at day
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Figure 2-12. Characterization of iPSC line BC1 derived from bone
marrow CD34+ cells by the single pEB-C5 plasmid. (A) Phenotypes of
expanded iPSC clone BC1 derived from BM CD34+ cells by the single C5
vector. Upper row for alkaline phosphatase (AP) staining and nucleus
staining of OCT4. Lower row for surface staining of SSEA4 and TRA-1-60.
Scale bar: 100 μm throughout. (B) Normal karyotypes of iPSC line BC1 at
various passages and another iPSC line derived from human peripheral

















Figure 2-13. Pluripotency assay of iPSC line BC1 derived from bone
marrow CD34+ cells by the single pEB-C5 plasmid. (A) The BC1 iPSCs
display normal pluripotency as assayed by embryoid body (EB) formation
and in vitro differentiation. Various cell types derived from ectoderm (β3-
tubulin), mesoderm (smooth muscle actin) and endoderm (alpha-fetal
protein, AFP) were found. (B) In vivo pluripotency of BC1 assayed by
teratoma formation. Both low (10×) and high (20×) magnification images of
multiple H & E stained sections were shown. Various cell types such as













Figure 2-14. Growth curves and phenotypes of expanded
mononuclear cells (MNCs) from cord blood (CB) or adult peripheral
blood (PB). (A) Plots of viable cells numbers at various days after thaw of
CB and PB MNCs at day 0 (defined as 100%). Mean +/- SEM of two
samples of CB and PB MNCs were shown. (B) Phenotypes of CB MNCs
before and after 8 days of culture. (C) Phenotypes of adult PB MNCs (from
SCD003) before and after 9 days of culture when cells were harvested for
flow cytometric analysis of surface marker expression and the remaining
cells for reprogramming by nucleofection with 1-2 plasmids. The FACS
gating was based on appropriate isotype controls of each monoclonal
antibody conjugated with a fluorochrome. After culture (day 8 or 9), very
few cells expressed markers for T cells (CD3, <3%), B cells (CD19,
<0.5%).
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Figure 2-15. Phenotypes of expanded mononuclear cells (MNCs) from
newborn cord blood. (A) After 11 days of culture when cells were
harvested for flow cytometric analysis of surface-marker expression and
the remaining cells for reprogramming by nucleofection with 1-2 plasmids.
The FACS gating was based on appropriate isotype-controls of each
monoclonal antibody conjugated with a fluorochrome. Percentages of each
population in two-color dot plots are indicated. The majority of cells
expressed pan hematopoietic cell marker CD45. Some cells resembled
erythroblasts that express a high level of CD235a (glycophorin A). Very few
cells expressed hematopoietic stem cell marker CD34. (B) Morphology of
expanded cells from CB MNCs. Benzidine staining of the cells cultured for
16 days, after being spun on slides. Most of cells after the 16-day culture













































































































Figure 2-16. Human iPSCs derived from cord blood (CB) mononuclear
cells (MNCs) by various EBNA1/OriP plasmids. (A) Reprogramming
efficiency of CB MNCs. Two different CB MNCs, frozen 1.5 months before
(GB/CB) and 13 years before (AC/CB), were cultured for 8 days. 2 × 106
cultured and primed cells were nucleofected by 1-3 EBNA1/OriP plasmids
as indicated. C5: pEB-C5; Tg: pEB-Tg; Combo 6: the Thomson/Yu
combination #6 (3 plasmids). The reprogramming proceeded as CD34+
cells described before, with or without sodium butyrate (NaB). Numbers of
TRA-1-60+ colonies (on day 14) per 106 nucleofected cells were plotted as
mean +/– SEM, n = 3. (B) The percentages of TRA-1-60+ colonies among







































































Figure 2-17. Growth curves and phenotypes of expanded
mononuclear cells (MNCs) from adult peripheral blood (PB) and
resulting iPSC line characterization. (A) Plots of viable cell numbers at
various days after thaw of PB MNCs. (B) Reprogramming efficiency of PB
MNCs. Two different PB MNCs, one from healthy donor and the other one
from patient were cultured for 10-14 days. 2 × 106 cultured and primed
cells were nucleofected by C5 or together with Tg. (C) Phenotypes of
expanded iPSC clone PE2 derived from PB MNCs cells by C5 and Tg
vectors. Upper row for nucleus staining of OCT4. Lower row for surface










Figure 2-18. Characterization of disease-specific iPSC line from a
HIF2α mutant patient by retroviral vectors. (A) Phenotypes of expanded
iPSC clone derived from HIF2α mutant PB CD34+ cells by regular retroviral
vectors. Upper row for nucleus staining of OCT4 and surface staining of
SSEA4. Lower row for surface staining of TRA-1-60. Normal karyotypes of
iPSC line at passage 15. Scale bar: 200 μm. (B) Demonstration of single
nucleotide mutation G A in HIF2α exon 6 by DNA sequencing, causing

















Figure 2-19. Pluripotency assay of iPSC line derived from HIF2α
mutant PB CD34+ cells reprogrammed by retroviral vectors in the
presence of sodium butyrate (NaB). (A) (B) in vitro differentiation assay
by embryoid body (EB) formation and differentiation. Various cell types
derived from ectoderm (β3-tubulin), mesoderm (smooth muscle actin) and
endoderm (alpha-fetal protein or AFP) were found. Scale bar: 200 μm. (C)
(D) In vivo differentiation assay by teratoma formation. The presence of
various cell types derived from all the 3 embryonic germ layers were
shown: neural rosette (ectoderm), adipose (mesoderm) and grandular
tissues (endoderm, yellow arrow) in representative images of H & E
stained sections. Scale bar: 200μm.
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Figure 2-20. DNA fingerprint to confirm the authenticity of iPSCs as
compared to their somatic cell origins. Genomic DNAs isolated from
various iPSC lines and their parental cells such as cord blood (CB), bone
marrow (BM) CD34+ cells and MSCs, and adult peripheral blood (PB)
mononuclear cells (MNCs). They were used as templates for detection of
variable regions (in size) in the genome by PCR using two sets of specific
primers from Invitrogen. The PCR fragments were separated by agarose
electrophoresis with size markers (in bp). Based on the results using two
sets of primers, derived iPSCs showed DNA fingerprints similar to their
parental cells, but distinct to other iPSC lines of different origins or two
human ESC lines (H1 and H9) we used at the time. For iPSC lines derived
from PB MNCs of a sickle cell disease patient (SCD003), we also confirmed
that they contain a homozygous mutation at the condon 6 of the β-globin
gene (by DNA PCR and sequencing).
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Chapter 3 
Functional Analysis of the iPSCs Derived 





In chapter 2, I have shown the EBNA1/OriP episomal vector can 
consistently reprogram various human postnatal blood cells. Compared to 
standard viral vector-mediated reprogramming, episomal vector has several 
advantages. First, a single transfection of episomal vector is sufficient for iPSC 
derivation, no need of multiple treatments or virus packaging. Second, the 
EBNA1/OriP vectors replicate once in a cell cycle, reducing DNA rearrangement 
and genome integration (Yates and Guan, 1991). Third, the episomal vectors 
gradually diminish in human cells, probably due to the silencing of the viral 
promoter deriving EBNA1 expression in iPSCs (Nanbo et al., 2007). Therefore, 
simple cell culture and passage may be enough to get rid of residual episomal 
vectors. 
Diminishing of episomal vectors in iPSCs requires many assays to prove it. 
So in this chapter I will verify the presence of episomal plasmid during and after 
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reprogramming. It is also equally important to test the pluripotency of iPSCs 
generated from episomal vectors in a more rigorous way. Since iPSCs were 
derived from blood cells, it is interesting to examine if blood-derived iPSCs have 
propensity for hematopoietic lineage re-differentiation.   
  
Approach 
The content of this chapter can be divided into 2 parts. The first part is to 
use multiple approaches to detect the presence of episomal vectors in derived 
iPSCs. I will start from regular PCR method to detect episomal vectors. I will also 
use southern blot as an additional method to confirm the result. However, these 
two approaches are non-quantitative assays. So I will take a quantitative PCR 
(QPCR) approach to investigate the dynamic change of episomal plasmid 
number in reprogrammed cells. Tracking the episomal plasmid number in 
transfected cells at different time points should provide better and more objective 
evidence. The ultimate method to rule out if episomal vector integrates into the 
human genome is to harvest both genomic and episomal (from mitochondria) 
DNA from derived iPSCs and undergo whole genome sequencing (WGS). By 
analyzing WGS, I can gain insight the integrity of the genome before and after 
reprogramming.  
The second part is to characterize the pluripotency of iPSCs derived by 
non-integrating plasmid. To collaborate with other researchers, I conducted direct 
differentiation of iPSCs to various lineages and confirmed the differentiation 




PCR to Detect the Existence of Episomal Vectors in Derived iPSCs 
Although EBNA1/OriP episomal vectors can reprogram a broad spectrum 
of blood cell types, the assumption of integration-free has not been validated. To 
this end, I extracted genomic DNA from cells before reprogramming (naïve cells) 
or cells 2 days post-nucleofection as negative and positive controls. Genomic 
DNAs from three different iPSC lines were tested: BC1 and PC1 are from BM 
and PB CD34+ cells respectively and C7 is from CB CD34+ cells (Figure 3-1). I 
designed primers specific to EBNA1 or Tg sequence to detect any residue of 
vector DNA using PCR. In general, a trace amount of EBNA1 DNA sequence 
(<0.2 copies per cell) could be detectable in iPSCs (C7) after reprogramming and 
expansion of 9 passages (about 50 days), but became undetectable by passage 
10-12 (all three lines, Figure 3-1A). Since all lines were reprogrammed by C5 
plasmid alone, no Tg sequence should be detected.  
Two characterized iPSC clones, CT5 and CTN4, which reprogrammed by 
C5+Tg were also analyzed by PCR to detect the presence of vector DNA EBNA1 
and Tg in expanded iPSCs at various passages. I again found that the plasmid 
DNA was undetectable after 10-12 passages of iPSC expansion (Figure 3-1B). 
I further used a third pair of primers which is specific to the junction of 
Sox2/Klf4 transgenes (in C5 plasmid) to check BC1 and 2 additional iPSC lines –
TNC1 and NC1. TNC1 and NC1 cell lines were reprogrammed from adult PB 
MNCs. In line with previous observations, I did not detect any sequence from 
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Sox2/Klf4 junction. My data are consistent with previous publications with 
reprogrammed human fetal or neonatal cells that the EBNA1/OriP episomal DNA 
in human iPSCs was spontaneously and gradually lost after reprogramming (Yu 
et al., 2009; Marchetto et al., 2009), likely due to methylation at EBNA1 and/or 
OriP DNA sequences resulting in silencing of EBNA1 expression and/or loss of 
OriP functions. 
 
Southern Blot Demonstrated the Absence of the Episomal Vectors 
I also conducted Southern blot analysis that is capable of detecting a 
single copy of vector DNA (Figure 3-2A, B). I found that the southern blot did not 
detect the vector DNA either as episomes or anywhere in the genome of NC1, 
TNC1, BC1 and C7 iPSCs. Table 3-1 summarizes the characterizations of 10 
most analyzed iPSC lines I derived from human blood cells by transient 
transfection of 1-2 episomal vectors. 
 
QPCR to Detect the Dynamic Change of Episomal Plasmid Numbers 
per iPSC at Different Passages 
Standard PCR only provides information of episomal plasmid 
presence/absence in established and expanded iPSC clones. To quantitatively 
measure the dynamic change of episomal vector in reprogrammed cells during 
the reprogramming and iPSC expanding procedure, I took the quantitative PCR 
(QPCR) approach. Two PCR primer pairs were designed; one is specific for 
EBNA1 sequence (EBNA1-primer) and the other one can recognize a small 
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fragment spanning the junction of Oct4 and Sox2 transgenes (OSJ-primer) 
(Figure 3-3A). EBNA1-primer or OSJ-primer was first used to run QPCR with 
different amounts of pEB-C5 plasmid and plotted the threshold cycle for the 
standard curve reactions against the fold dilution of the template C5 plasmid 
(Figure 3-3B). I can then determine the fit to a straight line including the slope 
and the correlation factor (Figure 3-3B). 
Next I performed another round of CB CD34+ reprogramming using pEB-
C5. Genomic DNA was extracted from day 2 nucleofection cells or derived iPSCs 
of various passages (Table 3-2). I loaded 100 ng of gDNA of different samples 
for QPCR reaction with either EBNA1- or OSJ-primer then got the Ct value and 
calculated corresponding episomal plasmid number. Table 3-2 was the QPCR 
result of plasmid copy numbers per iPSC at different passages. In the day 2 
sample, I can detect 363 copies of plasmid per cells. However, by iPSC passage 
6 or higher, the plasmid number decreased to 0.002 copies per iPSC. The data 
suggest that most of episomal plasmids were already diluted out. Higher 
passages of iPSCs also showed very low copy number of episomal plasmid. 
 
Whole Genome Sequencing Revealed Absence of Episomal Vector 
Sequence in the Genomes of the iPSC Lines 
PCR-associated assays provided a quick examination about existence of 
vector sequence C5 or Tg. But it is not the ultimate method especially if I want to 
look into the DNA level before and after reprogramming. With recently available 
technologies such as whole-genome sequencing (WGS) analysis, it is necessary 
76
to assess potential vector integration in the entire nuclear and mitochondrial 
genomes. I conducted WGS analysis to determine the DNA sequences of two 
human iPSC lines.  
The relationship of the two iPSC lines and their somatic cell ancestors are 
shown (Figure 3-4). BM CD34+ cells were used to generate the BC1 iPSC line 
after 4 day culture with pEB-C5. The second iPSC line BCT1 was derived from 
the same cultured CD34+ cells by C5 together with Tg. For the whole-genome 
DNA sequencing, expanded iPSC lines were cultured under a feeder-free 
condition (on matrigel) for at least one passage to reduce mouse feeder cells 
before total genomic DNA was extracted. In addition, DNA was extracted by the 
same method from the corresponding parental cells, i.e., the cultured CD34+ 
cells. My colleagues and I sequenced the iPSC lines BC1 and BCT1 with their 
parental somatic cells at the same time in a pair-wise fashion by Illumina HiSeq 
2000 technology. We obtained alignable DNA sequences around 130 Gbs for 
each iPSC line and their parental cells. The amount of sequence data is 
equivalent to 48 times or higher coverage of the haploid, nuclear genome. 
Sequence analysis indicated that we achieved high-quality coverage for more 
than 94% of the autosomal genome of each sample. This level of deep and pair-
wise sequencing of three related genomes (from the same person) provided us a 
high level of confidence to detect any integration of vector sequences.  
The deep sequencing of the total DNA (5 μg or from 800,000 iPSCs) 
provided more definitive evidence for the lack of vector DNA (either integrated or 
as episome) in these iPSC lines. I did not detect the pCEP4 vector backbone 
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sequence above background in any of the two sequenced iPSC lines derived by 
episomal vectors. Table 3-3 shows a summary of sequence analyses of the 
iPSC lines. 
 
Analysis of DNA Sequence Variations in Derived iPSCs in Comparison with 
Parental Somatic Cells 
When comparing to the human reference genome sequence (hg19), we 
identified approximately 4.2 million single-nucleotide variants (SNVs) in each of 
the iPSC lines as well as in their parental CD34+ cells and MSCs (Table 3-3). 
Some of these SNVs were aligned to repetitive regions of the reference genome 
(in parentheses). This level of sequence variations is comparable to those of 
other sequenced human genomes (Bentley et al., 2008; Ding et al., 2010; Lee et 
al., 2010; Pleasance et al., 2010; Ajay et al., 2011). When the sequences 
between each iPSC line and its parental cells were directly compared, 1,058 to 
1,808 likely SNVs were identified between each iPSC line and its parental 
somatic cells sequenced in pairs (Table 3-3). All SNVs found in iPSCs were 
heterozygous (i.e., single-allele) changes as compared to their parental somatic 
cells. Importantly, none of these iPSC-associated SNVs are shared among the 
three iPSC lines. Neither did we observe any clustering of these variations in 
specific chromosomal regions. 
 
SNVs in Known Functional Elements of the Genome 
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To investigate functional relevance of SNVs found in iPSCs after induction 
and expansion, we next focused on SNVs in exons, especially those not present 
in dbSNP (build 132) database as reported previously. High-quality sequencing 
revealed six SNVs in BC1 iPSCs residing within the coding regions of six 
different genes (Table 3-3, 3-4). Three of them are non-synonymous (Table 3-3, 
3-4). The paired sequencing data also revealed six SNVs in coding regions of six 
different genes in BCT1 iPSCs (derived from the same CD34+ cells); two of them 
are non-synonymous (Table 3-3, 3-4). Of the 1,058 SNVs between BC1 iPSCs 
and CD34+ cells, only 2 lie in a CpG island near a promoter, and none lie within 
the sno/microRNA regions in the UCSC’s sno/microRNA track. For BCT1 iPSCs, 
there were no SNVs in the CpG islands but one in the micro RNA mir-124-2 
(Table 3-3). 
 
Blood Lineage Differentiation of iPSCs Generated from Human Blood Cells 
by Non-Integrating Plasmids 
In addition to embryoid body (EB) formation for in vitro spontaneous 
differentiation (Figure 2-10A), I also conducted direct differentiation of BC1 
iPSCs to hematopoietic lineages. Known numbers of dissociated BC1 iPSCs 
were deposited in round-bottomed, 96-well plates and then aggregated the cells 
into EBs by centrifugation. Cytokines that stimulate mesoderm and hematopoietic 
specification were supplemented at different time points. By day 10-12, single 
rounded and blood-like cells can be observed at the edge of EBs (Figure 3-5A). 
All single cells were harvested on day 18 and stained by a panel of blood 
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markers. Fluorescence-Activated Cell Sorting (FACS) analysis showed 78% of 
cells were CD45+ and 60% of cells were CD34/CD45 double positive, the former 
indicated properties of blood cells and the later showed the generation of blood 
progenitors (Figure 3-5B). Fifteen thousand cells were also taken for colony 
forming cell (CFC) assay in total 3 wells. After 2 weeks, various colonies were 
observed with different colony forming units (CFUs) (Figure 3-6A, B). The data 
show the iPSCs can differentiate to blood cells. 
Some harvested single cells from EBs were put in suspension culture for 
erythroblast expansion and maturation. By day 10, cells were subject to FACS 
analysis and found 9% of cells were positive for erythroblast marker CD235a 
(glycophorin A) (Figure 3-7A). The data suggested that BC1 iPSCs possess the 
potential for erythroblast differentiation. In a parallel assay, my colleagues and I 
cultured suspension cells from BC1 EBs for megakaryocyte differentiation for 5 
days. We can detect the expression of megakaryocyte markers CD41a and 
CD42a in differentiated cells, indicating they committed to megakaryocyte 
lineage (Figure 3-7B; unpublished data). Taken together, the data show that 
iPSCs derived from human postnatal blood cells by non-integrating plasmids can 
differentiate into multiple blood lineages. 
 
Non-blood Differentiation of iPSCs Generated from Human Blood Cells by 
Non-Integrating Plasmids  
My colleagues and I also tested BC1 cell line’s differentiation potential to 
non-blood lineages. When we cultured BC1 iPSCs in a condition to promote 
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mesenchymal stem cell (MSC) differentiation, expression of surface markers 
CD73, CD271 CD256 and CD146 can be detected (Figure 3-8A). The 
differentiated cells can also form colony forming unit fibroblasts (CFU-F) (Figure 
3-8B, left) or stained positive for Alizarin red which can identify calcium in 
osteogenic differentiation cells (Figure 3-8B, right). 
Moreover, collaborators also showed BC1 can be successfully induced to 
Schwann cells, peripheral nervous system cells (Figure 3-9) (Liu et al., 2012) 
and astrocytes (Figure 3-10) (Shaltouki et al., 2013). These molecular and 
cellular results demonstrated that blood-derived iPSCs by episomal vectors have 
multi-lineage differentiation capacity.   
 
Discussion 
Using PCR (3 sets of specific primers) and Southern blot, I showed 
episomal vector DNA did not exist either as episomes or anywhere in the 
genome of the iPSCs analyzed. The whole genome sequencing analysis 
provided additional evidence all vector DNA has been lost. These results 
demonstrated that reprogramming human somatic cells does not require 
genomic integration or continuous presence of exogenous reprogramming 
factors and thus removes one obstacle to the clinical application of human iPSCs. 
In the future, it would be useful to build a method that can eliminate episomal 
vector DNA more efficiently than the passive expansion and dilution approach. 
Interestingly, I noticed that all 5 of the iPSC lines derived from blood cells 
by non-integrating vectors we analyzed so far clustered together (and close to a 
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group of hESC lines), based on promoter DNA methylation signatures. They 
appear distinct from other iPSCs derived by integrating vectors from either blood 
CD34+ cells or MSCs/fibroblasts (Figure 2-1). A recent study found that mouse 
blood cell-derived iPSCs more closely resemble ESCs epigenetically and 
functionally than those derived from fibroblasts (Kim et al., 2010). Whether the 
virus-free and integration-free human iPSCs derived from blood cells and by the 
non-integrating vectors are superior in quality (closer to the best human ESCs) 
than previous iPSC lines derived by integrating vectors remains to be determined. 
Increasing evidence suggests that both DNA replication-dependent and -
independent mechanisms are involved in promoting reprogramming, which is 
fundamentally an epigenetic process (Hanna et al., 2009). My studies in 
generating iPSCs from unfractionated human blood MNCs depends on a culture 
condition to obtain a proliferating cell population that is neither T nor B cells, 
before plasmid-mediated reprogramming. I will work on finding a refined culture 
condition to shorten the culture period from current 10-14 days to 2-4 days. It is 
also of interest to determine if the serial delivery of synthetic mRNAs encoding 4-
5 reprogramming factors or purified proteins could reprogram human blood 
MNCs more efficiently than human fibroblasts as reported.  
The facile method described here that reprograms blood cells after 
minimal culture and using plasmids provides several important advantages over 
other virus-free and integration-free methods. First, one-time delivery of 1-2 
plasmids that are much easier to produce and more stable than proteins or 
mRNAs makes the method more attractive or feasible for generation of clinical 
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grade iPSCs under current good manufacture practice (cGMP) conditions. 
Second, the capability to reprogram PB MNCs not only provides a readily 
available source of human cells for iPSC derivation (Yamanaka, 2010), but also 
shortens the cell culture time required to prepare and prime the target cells for 
reprogramming (now < 14 days from blood versus ≥ 4 weeks from skin biopsies). 
We can harvest PB MNCs directly from patients and make cells become patient- 
or disease-specific iPSCs. Patient-specific iPSCs represent a valuable tool to 
study poorly understood mechanisms of hematological diseases. My combined 
method of using MNCs from a few milliliters of blood and non-integrating 
plasmids brings the iPSC derivation technology to a new level, and offers greater 
promise for the use of patient iPSCs for disease modeling and future clinical 
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Figure 3-1. Detection of episomal vector sequence by PCR. (A) PCR-
based detection of vector sequence EBNA1 and Tg in 3 iPSC lines derived
from human various CD34+ cells by the single C5 vector. (C7: cord blood,
BC1: bone marrow, PC1: mobilized peripheral blood). The single-copy
cellular sequence β-actin was used as a quality control for isolated
genomic DNA. Total DNA isolated from the cells before (naïve) and after
nucleofection (day 2) were used as negative and positive controls for
vector DNA. The pEB-Tg plasmid diluted in amounts equivalent to 1, 0.2 or
0.04 copies per genome of cellular DNA was used as a control for detection
of the EBNA1 viral DNA sequence. (B) Two additional CB CD34+ cell
derived iPSC lines by C5 together with Tg (CT5 and CTN4) were included.
Genomic DNA was examined to detect the presence of EBNA1 or Tg
sequence. (C) Another set of primers specific to Sox2/Klf4 junction
sequence was used. TNC1 and NC1 iPSC lines were from PB MNC
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Figure 3-2. Southern blot analyses for the lack of vector DNA in
expanded iPSCs that are derived by episomal vectors. (A) Detection of
vector DNA sequences using EBNA1 DNA as a probe. Total DNA isolated
from various cell extracts (lane 1-6) was digested by BamH I and separated
by 0.7% agarose gel. Peripheral blood MNCs before (naïve, lane 1) and after
nucleofection by two plasmids pEB-C5 and pEB-GFP at day 2 (lane 2) were
included. Total DNA isolated from 4 iPSC lines were analyzed here: NC1
(passage 16, lane 3), TNC1 (passage 20, lane 4), BC1 (passage 28, lane 5)
and C7 (passage 31, lane 6). 5 μg total DNA isolated from various cell types
were used, except that only 0.5 μg DNA (10%) from the day 2 transfected
cells was used in lane 2. Plasmid DNA of pEB-C5 was also cut (once) by
BamH I, and used as a positive control in the detection (lane 7-9). Plasmid
DNA was loaded in limiting dilutions (12 pg in lane 7, 120 pg in lane 8 and 1.2
ng in lane 9). The numbers of loaded vector DNA molecules per lane, relative
to the copy numbers of nuclear genome of naïve cells and iPSCs, would be
0.8x, 8.0x and 80x, respectively. Ladder: DNA size markers. (B). Quality
controls of genomic DNA isolated from 4 iPSC lines. The same genomic DNA
samples were digested and analyzed by Southern blot. The probe used was a
cellular DNA fragment 3’ to the HBB gene. As expected, the method detected
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Figure 3-3. QPCR to detect the dynamic change of episomal plasmid
numbers in reprogrammed cells. (A) Two primers specific for EBNA-1
sequence or sequence crossing Oct4 and Sox2 transgenes were
designated. (B) The threshold value of different amount of plasmid were
derived to determine the standard curve.
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Estimated plasmid copy #/cell
2 days after 
nucleofection 363.743




Table 3-2. QPCR results of plasmid copy number per iPSC. 363
copies of plasmids per cell in the sample of 2 days after transfection.
After passage 6 or higher, the plasmid number almost decreased to 0.
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Bone Marrow Mononulear Cells from a










After 4 days in Culture
BCT1 iPSC
C5+Tg reprogramming   
S4
CD34+CD45+
Figure 3-4. Relationship of iPSC lines and their parental somatic cells
used in this study. Mononuclear cells from bone marrow (BM) of healthy
adult donor (BM 2426) were separated into CD34+ cells (∼1%) and CD34
depleted (CD34-) cells. The CD34+ cells were cultured for 4 days with
hematopoietic cytokines before being reprogrammed by episomal vectors
(left). The BC1 iPSC line was derived by using a single plasmid pEB-C5
whereas the BCT1 iPSC line was derived by addition of a second plasmid
pEB-Tg. The BM CD34− cells were used to establish cultures of marrow
stromal cells. This was done in pair with the parental somatic cells (also
boxed). BC1 and BCT1 iPSC lines were derived from the same batch of
CD34+ cells cultured for 4 days.
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Table 3-3. Summary of sequencing two pairs of iPSC lines and their
parental somatic cells. No episomal vector sequence was found in iPSC
lines BC1 and BCT1.
Features/iPSC lines BC1 BCT1
Passages 25 18
Total nucleotides sequenced 172 Gb 153 Gb
Alignable nucleotides 165 Gb 142 Gb
Genome coverage (fold) 59X 51X






Filtered single nucleotides variants 
(SNVs) 1058 1109
SNVs shared between BC1 and BCT1 No No
SNVs cluster in specific chromosome 
region No No
SNVs selectively enriched in oncogenes No No
SNVs in coding regions 6 6
Synonymous (S) 3 4
Nonsynonymous (NS) 3 2
SNVs in CpG islands 2 0
SNVs in sno/microRNA regions 0 1
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iPSC Lines Gene Name Chromosome Position Ref Allele
Variant 
Allele Variant Type
BC1 CNBD1 8 88365930 G A nonsynonymous
ITGA11 15 68650878 T C nonsynonymous
SLIT2 4 20490512 C T nonsynonymous
DHX34 19 47865827 C T synonymous
DOCK1 10 128836023 C T synonymous
PRPS1L1 7 18066668 A G synonymous
BCT1 ADAMTS17 15 100657067 C T nonsynonymous
TG 8 133961089 C T nonsynonymous
CDH4 20 60318830 G A synonymous
EPPK1 8 144941146 G C synonymous
MCM10 10 13213236 C A synonymous
OR8K1 11 56113928 C T synonymous
Table 3-4. Sequence variants in the coding regions in BC1 and BCT1
iPSCs
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Figure 3-5. Morphology and phenotypes of BC1 iPSC derived
hematopoietic cells. (A) Rounded hematopoietic cells emerged from EBs.
(B) Emerged cells can express CD45 and CD34 markers. 60% of cells
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Figure 3-6. CFC potential of BC1 iPSC derived hematopoietic cells.
(A) BC1 derived hematopoietic cells by EB formation were plated to 3
methylcellulose plates. Different colony forming units were identified and
counted on day 14. (B) Human iPSCs derived from postnatal blood cells
readily gave rise to multiple blood cells including erythroid progenitors. 10X
magnification. Abbreviations: CFU-E (colony forming unit-erythroid); CFU-
GM (colony forming unit-granulocyte/macrophage); CFU-M (colony forming











Figure 3-7. Erythroblast and megakaryocyte differentiation of BC1
iPSCs. (A) Surface antigen profiling by FACS in BC1 iPSC derived
erythroblasts for erythroblast marker CD235a (glycophorin A). (B) BC1




(Unpublished data, Gao, Y)
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Figure 3-8. Mesenchymal stem cell differentiation of BC1 iPSCs. (A)
Surface antigen profiling by FACS in iPSC derived MSCs for CD73,
CD271, CD256 and CD146. (B) Left: Morphology of BC1 derived MSCs
stained by Crystal Violet-stained colonies. 20X magnification. Right:
osteogenic differentiation by Alizarin Red staining. 20X magnification.
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Figure 3-9. BC1 iPSCs can differentiate to Schwann cells and PNS
neurons. (A) The cells emigrating out of the rosettes of BC1 iPSCs were
live stained by p75 and could be purified by FACS. Cultured neural crest
stem cell expressed Sox9 (B). (C-F) BC1 iPSCs can differentiate into
neural stem cells and give rise to S100β+ Schwann cells (C), peripherin+
sensory neurons (D), and sympathetic neurons positive for TH and a
noradrenergic marker DBH (E-F). Abbreviations: TH, tyrosine hydroxylase;




Figure 3-10. Differentiation of BC1 iPSCs into astrocytes. (A) BC1
differentiated for 5 weeks in defined medium displayed high percentage of
glial fibrillary acidic protein (GFAP) immunostaining. (B) Cytoplasmic co-
localization of S100β and GFAP in 4 weeks differentiated BC1. Scale bars,




Engineering Human Induced Pluripotent 
Stem Cells for GFP and Hematopoietic-




Genetic manipulation of human pluripotent stem cells (hPSCs) provides a 
versatile tool to study stem cell differentiation, trace lineage commitment and 
may develop potential therapeutic applications. In the previous chapters, I have 
shown the evidence to derive human iPSCs from human blood cells via episomal 
vectors. In this chapter, I will address the application of genetically modified 
iPSCs for future differentiation tracking or lineage specification. 
The green fluorescent protein (GFP) gene can be introduced and 
expressed in mammalian cells through transfection or virus infection. It has been 
widely used in cell and molecular biology as a biomarker (Tsien, 1998). Since 
iPSCs can proliferate indefinitely, labeling cells with long term expression of GFP 
would be useful to study the mechanisms governing differentiation. In the in vivo 
study, I can also detect GFP signal to locate the migration of iPSCs or determine 
cell origin. 
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Besides ubiquitous GFP expression iPSCs, generation of lineage-specific 
fluorescent protein reporters in human PSC lines also benefits researchers to 
investigate crucial mechanisms involved in lineage specification. Moreover, I can 
also isolate certain cell populations by cell sorting for detailed studies. 
Wiskott-Aldrich Syndrome (WAS) is an X-linked recessive disease 
accompanied with thrombocytopenia, eczema and immunodeficiency (Massaad 
et al., 2013). It has been shown that WAS gene is only active within 
hematopoietic lineages including very immature cells (Parolini et al., 1997). 
Further studies also identified a short element of 170 nucleotides upstream of the 
WAS coding sequence regulates the expression of WAS gene (Petrella et al., 
1998). These findings inspired me to engineer an iPSC line so that all blood cells 
differentiating from iPSCs can display GFP signal. This kind of reporter system 
will provide an exceptional opportunity to study how hematopoietic differentiation 
happens in stem cells and improve current differentiation protocols. 
The RUNX1/AML1 gene is an important regulator for the development of 
definitive hematopoiesis in both mouse and human (Yamagata et al., 2005; Blyth 
et al., 2005). Loss of function of RUNX1 in murine embryo results in lethal 
phenotype due to lack of any definitive blood cells (North et al., 1999; Wang et al., 
1996). However, the transcriptional regulation of this gene is largely unknown. In 
one previous study, researchers used comparative genomics and chromatin 
analysis to identify a conserved 531-base pair enhancer in the first intron of 
mouse RUNX1 gene (Nottingham et al., 2007). This enhancer plays an important 
role in RUNX1 gene expression. More strikingly, it targets reporter gene 
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expression to all known hematopoietic tissues of the mouse embryo which is 
similar to endogenous RUNX1 gene expression (Nottingham et al., 2007). In light 
of this result, I wonder if I can take advantage of this enhancer element to 
generate a reliable hematopoietic reporter system in iPSCs. 
 
Approach      
Genetic modification of human PSCs is not an easy task due to very low 
efficiency of delivery methods. Currently, gene transfer into human PSCs is 
largely based on the use of viral vectors. In the meanwhile, the transgenes in 
human genome are susceptible to transcription-dependent silencing. Thus 
finding an efficient transfection method is the key toward generating a faithful 
reporter system in human PSCs.  
The piggyBac (PB) transposon is a mobile genetic element that efficiently 
jumps between vectors and chromosomes through a "cut and paste" mechanism. 
In contrast to retro- or lenti- virus-mediated genome integration which may 
activate gene expression around the integration sites, the PB transposon causes 
a relative stable integration in the human genome (Wilber et al., 2007; Wu et al., 
2006). PB not only efficiently mediates gene transfer into the mammalian cells 
but also can be precisely excised, leaving no trace sequence behind.     
In the first part of my goal, I will use an optimized PB transposon system 
to mediate gene transfer for GFP expression under the control of a ubiquitous 
promoter to one of iPSC line. Next, I will combine the WAS promoter fragment 
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and the RUNX1 enhancer element to test the idea of creating a hematopoietic 
reporter iPSC line. 
 
Results 
Generation of Stable GFP Expression iPSC Line by piggyBac Transposon 
System  
To test PB delivery experiments, I selected human iPSC line BC1 which 
was reprogrammed by single pEB-C5 vector from healthy adult bone marrow 
CD34+ cells (id=BM2426) as the model. I have demonstrated the pluripotency 
and normal karyotype of this cell line. I also confirmed there is no pEB-C5 vector 
sequence left in the genome, demonstrating it is a footprint-free authentic iPSC 
line.   
The standard PB system can be divided into a donor plasmid that contains 
the transposon and a helper plasmid that expresses the transposase (Cary et al., 
1989; Wilson et al., 2007). I constructed the GFP gene under the control of CAG 
promoter in PB vector. BC1 iPSCs were cultured as previously described (Chou 
et al., 2011) and 1 million cells were harvested and dissociated to single cells. 
Equal amount of transposon and transposase were transfected through 
nucleofection into BC1 cells (see Methods). GFP+ cells can be detected 48 hours 
after nucleofection (Figure 4-1A). I performed puromycin selection for 7 days to 
allow successful integrated and stable GFP+ cells to grow. Next I used cell 
sorting to collect the brightest cells and reseeded them back to standard iPSC 
culture in order to pick up individual clones (Figure 4-1B). 
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One representative clone (GFP-BC1) is shown (Figure 4-1C). This clone 
has been cultured for 67 passages and with no sign of decreased GFP 
percentage or intensity. Taken together, I derived a stable GFP expression iPSC 
line that can be beneficial for future in vivo or lineage tracking studies. 
 
Generate RUNX1-Enhancer/WAS-Promoter Driven piggyBac Vector as the 
Hematopoietic-Specific Reporter   
The original WAS 170-bp promoter was in lentiviral vector to drive a 
downstream GFP gene (leuci et al., 2009). I first transfected this construct to 
k562 cell line and confirmed the strong expression of GFP signal in 
hematopoietic cells (Figure 4-2B). However, the original LV vector did not 
contain any selection gene, so I sought to clone the hematopoietic-specific 
reporter fragment to PB vector. WAS-GFP fragment was PCR amplified in order 
to create new restriction enzyme cutting sites and then inserted into empty PB 
vector (Figure 4-2A, left). In addition, I also wanted to test if including the 
RUNX1 enhancer to WAS-GFP-PB construct can have additive effect for labeling 
hematopoietic cells. The RUNX1 enhancer element was obtained by PCR 
amplification from human iPSCs and subsequently cloned to TOPO vector. Then 
the enhancer element was separated from TOPO vector and cloned upstream of 




Specific Marking of iPSC-Derived Hematopoietic Lineage by the RUNX1-
Enhancer/WAS-Promoter Driven piggyBac Vector  
The indefinite expansion potential of human iPSCs allows for clonal 
selection of individual transgene-modified clones. Therefore, I sought to 
nucleofect the two hematopoietic-specific reporter constructs: WAS-GFP-PB and 
RUNX1-WAS-GFP-PB to human iPSC line BC1. A parallel CAG-GFP-PB 
construct was also used as efficiency and experimental controls. After 
nucleofection and antibiotic selection, individual clones were picked and 
expanded. I defined nucleofected cells as BC1 reporter iPSCs to distinguish from 
intact BC1 iPSCs. 
I first confirmed BC1 reporter iPSCs did not express GFP signal (Figure 
4-2C). The hematopoietic differentiation potential of BC1 derived from three 
different constructs was examined by an improved method of EB formation and 
differentiation under a feeder- and serum-free condition (Yu et al., 2009; Ng et al., 
2005; Ng et al., 2008). I did not observe any GFP expression in EBs in the first 
several days of hematopoietic differentiation. Strikingly, when single cells 
displaying blood cell morphology started to emerge from BC1 reporter EBs from 
day 9, I sporadically detected some cells were coincident with GFP expression 
(Figure 4-3A).  
To further identify the phenotype of these GFP+ cells, all single cells were 
harvested from day 10 EBs for surface marker staining and FACS analysis. 
Undifferentiated BC1 iPSCs were negative for pan-hematopoietic marker CD45 
and progenitor marker CD34 (Figure 4-4A). However, about 63% of 
109
differentiated cells showed CD45+ and 37% of cells were dual positive for CD45 
and CD34 (Figure 4-4B), indicating the high efficiency of EB hematopoietic 
differentiation. In particular, I observed 35% of single cells were GFP+, indicating 
the reporter GFP gene was expressed in BC1-derived hematopoietic cells. 
Although not all CD45+ cells were GFP+, most GFP+ cells indeed showed 
CD45+ marker (Figure 4-4B). I did not observe obvious difference between 
WAS-GFP-PB and RUNX1-WAS-GFP-PB constructs. Taken together, our 
preliminary data showed the functionality of hematopoietic-specific reporter 
system. It may help us to improve our protocol for a more efficient blood 
differentiation or study hematopoiesis in EBs. 
          
Discussion 
Genetic manipulation of human iPSCs to establish a reporter system is 
crucial to study stem cell lineage specification. It requires the capability to 
efficiently express a reporter gene. In this chapter, I first used piggyBac vector to 
deliver the GFP gene to the iPSCs derived in previous chapters. After selection 
and colony picking, one clone was picked and it displayed stable GFP expression 
with high intensity. My data showed even after blood lineage differentiation, most 
differentiated cells maintained GFP expression, suggesting the fidelity of GFP 
reporter. This cell line could be helpful for in vivo differentiation tracing.  
I also took one step further to generate the hematopoietic-lineage specific 
reporter. The GFP expression is under the control of the WAS promoter and the 
RUNX1 enhancer, both which were reported to express in hematopoietic lineage 
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cells exclusively. I first confirmed iPSCs bearing this reporter construct did not 
express GFP, but upon hematopoietic differentiation, GFP signal were expressed 
in iPSC-derived hematopoietic cells. Detailed FACS analysis showed most GFP+ 
cells co-localized with hematopoietic markers CD45/CD235a. However, only 
partial CD45+/CD235a+ cells were marked with GFP. To rule out the possibility 
that the BC1 reporter cell line originated from more than one clone, I dissociated 
the cell line to the single cell level for subclones. Subsequent differentiation 
assay showed GFP+ was still tagged in partial CD45+/CD235a+ cells. In addition, 
WAS/RUNx1 vector also marked a subpopulation of CD34+ cells. Whether 
GFP+CD34+ population can generate more CD45+ cells than GFP-CD34+ cells 
remains to be determined.   
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Figure 4-1 Genetic labeling of BC1 iPSCs with GFP via piggyBac
transposon vector nucleofection. (A) GFP signal can be detected in BC1
iPSCs 48 hours after nucleofection. (B) Nucleofected cells dissociated to
single cell level were collected by cell sorting for the brightest population.















Figure 4-2. Expression of WAS-promoter driven piggyBac in blood
cells. (A) Representation of the piggyBac vectors used to nucleofect
human iPSCs. WAS-GFP-PB vector contains a 170-bp fragment of the
human Wiskott-Aldrich Syndrome (WAS) gene proximal promoter driving
the reporter gene GFP. In another set of reporter vector, a RUNX1
enhancer element was cloned to the upstream of WAS proximal promoter.
(B) K562 cells infected by the original lentiviral vector containing WAS-GFP
fragment showed GFP signal, proving the functionality of WAS-GFP
cassette in hematopoietic cells. (C) GFP was not expressed in
undifferentiated BC1 reporter iPSCs nucleofected with WAS-GFP-PB or










Figure 4-3. Specific expression of GFP in BC1 iPSC derived
hematopoietic cells. (A) BC1 reporter iPSCs nucleofected by RUNX1-
enhancer/WAS-promoter vector became GFP positive after EB formation
for direct blood differentiation. (B) More blood-like single cells emerged
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Figure 4-4. Hematopoietic differentiation induces GFP expression in
RUNX1-WAS-PB and WAS-PB nucleofected BC1 reporter iPSCs. (A)
Undifferentiated BC1 iPSCs did not express blood-related markers: CD34
, CD45 or CD235a. BC1 iPSCs were also negative for GFP. (B)
RUNX1/WAS-PB and WAS-PB nucleofected BC1 reporter iPSCs were
prompt to blood differentiation and analyzed for GFP expression 10 days
later. Isotype control was shown in the top row. Gated cells were subject
for blood marker analysis (mid row left). Abundant cells expressed CD34 ,
CD45 or both markers, (mid row right). Some cells also showed GFP
signal and partially co-localized with CD34 marker (framed, bottom row
left). Not all CD45+ cells were GFP, but almost all GFP+ cells were
coincident with CD45 marker (framed, bottom row right).
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Chapter 5 
Direct Reprogramming of Human Lineage 
Committed Blood Cells to Hematopoietic 




Stem cells hold great promise for cell therapy, especially hematopoietic 
stem/progenitor cells (HSPCs), the only stem cell type that has been widely used 
in bone marrow transplantation. HSPCs are a rare population and are defined by 
their ability to self-renew and give rise to all blood cell types. They are 
responsible for replenishing billions of blood cells every day. The classic sources 
of HSCs include umbilical cord blood (UCB), bone marrow (BM) and granulocyte-
colony stimulating factor (GCSF) mobilized peripheral blood (mPB) (Yan et al., 
1995). Although HSCs are a valuable model to study stem cells, the difficulty of 
expanding HSCs under defined, in vitro conditions impedes our understanding of 
hematopoiesis and also limits the potential clinical use of HSCs. 
Efficient differentiation of pluripotent stem cells (PSCs) such as embryonic 
stem cells (ESCs) and iPSC into HSCs provides an alternative for generating 
HSCs and has been extensively pursued in the past three decades. Many in vitro 
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differentiation systems have been developed, either mediated by embryoid body 
formation or by co-culture with stromal cells lines such as OP9, a mesenchymal 
cell line derived from a mutated mouse strain with M-CSF deficiency (Nakano et 
al., 2009). Generation of various myeloid cell types from mouse and human 
PSCs, and even some lymphocytes at lower efficiencies, have been reported by 
many groups (Daley, 2003; Choi et al., 2009; Doulatov et al., 2013; Potocnik et 
al., 1994; Liang et al., 2013). However, the in vitro derived hematopoietic cells 
from PSCs typically resemble embryonic or primitive hematopoietic cells and lack 
robust in vivo engraftment and repopulation activities in conditioned recipient 
mice. Genetic manipulation such as overexpression of HoxB4 and other 
transcriptional factors in mouse ESCs can produce transplantable mouse HSCs 
(Kyba et al., 2002), although it is more skewed towards myeloid cells. However, 
this approach is less effective with human PSCs (Unger et al., 2008; Lee et al., 
2008) as HoxB4 overexpression in human ESCs or even postnatal HSCs 
enhanced the growth of more differentiated myeloid progenitor cells instead of 
HSCs.   
The studies of transcription factor (TF) -mediated cellular reprogramming or 
direct cell conversion question the long-held traditional concept that cell fate is 
not interchangeable (reviewed by Ladewig et al., 2013). By collecting lineage-
specific TFs that are responsible for maintaining the target cells or inducing 
differentiation pathway toward the final products, many groups have reported 
trans-differentiation or direct conversion to neurons, cardiomyocytes and blood 
cells in mouse and human cells (Vierbuchen et al., 2010; Ieda et al., 2010; Qiang 
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et al., 2011; Pfisterer et al., 2011; Son et al., 2011; Marro et al., 2011; Pang et al., 
2011; Caiazzo et al., 2011; Pereira et al., 2013). However, the process of 
selecting and optimizing the best lineage-specific TF combination for direct 
reprogramming is arduous and lengthy. It is unlikely that every time we can start 
from a pool of candidate genes, then narrow down to final essential factors. In an 
effort to devise a more general approach for dedifferentiation, a universal TF 
combination would be attractive.  
In 2010, one group first showed the single OCT4 gene can directly 
reprogram human fibroblasts to multi-lineage blood progenitors (Szabo et al., 
2010). Soon after, other groups demonstrated that the standard Yamanaka four 
factors can be used for direct reprogramming, instead of iPSC generation (Efe et 
al., 2011; Kim et al., 2011). In these reports, contractible cardiomyocytes or 
neural stem cells were derived. The underlying principle is that the four 
reprogramming factors bring cells to an epigenetically plastic and fate-
undetermined intermediate (Figure 5-1). Providing appropriate developmental 
cues and culture conditions can guide cells toward a desired cell lineage. 
Reprogramming to pluripotency is just one of many possibilities after the four 
iPSC factor induction. Previous reports also have shown partially reprogrammed 
or intermediate stage cells displaying multiple lineage-specific markers 
(Mikkelsen et al., 2008; Meissner et al., 2007; Silva et al., 2008; Maherali et al., 
2007; Sridharan et al., 2009; Thier et al., 2012; Matsui et al., 2012). These 
findings led me to ask whether the standard Yamanaka four factors Oct4, Sox2 
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Klf4 and c-Myc and appropriate culture conditions can directly reprogram 
differentiated somatic cells to HSPC. 
 
Approach 
To test the hypothesis that HSPCs can be directly reprogrammed from 
lineage committed cells, it is crucial to select an appropriate starting cell 
population. Human fibroblasts are the most studied cell type for direct 
reprogramming, but their epigenetic signature may be distant from the targeting 
cells--HSPCs. A cell type that is close to HSPC signature and easy to obtain and 
expand is ideal. Besides, an intra-lineage direct reprogramming may be more 
feasible to achieve. In previous chapters, I have developed a culture condition to 
expand various human blood mononuclear cells (MNCs) to erythroblast lineage 
(Figure 5-2). The expanded erythroid cells were positive for pan-hematopoietic 
marker CD45, indicating they remained the cells within the blood lineage. The 
exhibition of erythroblast markers after culture provides another advantage that 
they are erythroid lineage committed cells, and largely reduce HSPC 
contamination. I will focus on cord blood (CB) derived lineage committed cells 
because CB has higher growth potential and versatility than adult blood and may 
decrease the threshold of direct reprogramming. 
Viral vector is still one of the most widely used methods to delivery 
transgenes to mammalian cells. But many viral vector-mediated reprogramming 
methods rely on multiple viral vectors to express individual reprogramming 
transgenes which result in multiple proviral copies throughout the genome and 
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the expression of each transgene is differential. Thus I decided to use a single 
retro viral vector expressing four reprogramming factors linked by 2A self-
cleaving peptides to conduct direct reprogramming (Zhang et al., 2011). The 
polycistronic expression of four reprogramming factors from the same promoter 
should reduce the viruses necessary for reprogramming and make every time 
infection more consistent. In addition, the co-expression of GFP also helped me 
to track reprogrammed cells and served as an indication of transgene expression.  
In addition, finding appropriate culture conditions to culture reprogrammed 
cells and support HSPC growth is important. Multiple growth factor combinations 
have been documented for supporting HSC expansion in vitro (Sauvageau et al., 
2004). OP9 stromal cell co-culture systems and serum free culture conditions 
were also reported (Nakano et al., 2009). I will test variant culture conditions to 
expand potentially reprogrammed HSPC-like cells. Although the condition may 
not sustain the long term HSPC propagation, a short proliferation period should 
be enough to catch the cells for characterization. 
 
Results 
Characterization of Human Cord Blood Mononuclear Cells after 
Erythroblast/Megakaryocyte Expansion   
Obtaining suitable blood cells as a starting population is critical for the 
direct reprogramming. It should remain in the blood lineage with capability to 
proliferate but lack HSPC features. Toward this end, I employed the method my 
colleagues developed for erythroblast lineage growth from human blood 
mononuclear cells (MNCs). Human cord blood (CB) MNCs were thawed and 
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cultured for erythroid cell expansion. During 10-14 days of culture, the cell 
number first dropped but rebounded around day 4 (Figure 5-3A). By day 10, 
cells kept growing and displayed morphology of typical blood cells (Figure 5-3B). 
FACS analysis confirmed most of cells remained pan-hematopoietic marker 
CD45+ (>99%) (Figure 5-4) and expressed erythroid progenitor marker CD36+ 
(>98%) (Figure 5-4), indicating the characteristics of erythroid-specific cells. My 
data showed ~34% of cells also expressed erythroid cell specific marker CD235a 
(glycophorin A) (Figure 5-4). In addition, only very few percentage of cells 
expressed CD34+ (<1%) and these minor cells will be excised by cell sorting 
(Figure 5-4). The expanded population contained rare TRA-1-60+ cells which is 
a surface marker for pluripotent cells (Figure 5-4). The signal was quite weak 
and could be just non-specific staining. Most cells were dim or negative for 
megakaryocyte markers CD41a and CD42a.  
The expanded cells were first sorted based on CD45+ marker to exclude 
out any non-hematopoietic cells (Figure 5-5A). To ensure staring cells are free of 
HSPC contamination, only CD34- cells were sorted because HSPCs are 
enriched in CD34+ population. I also sorted cells expressing CD36 marker which 
is a common accepted marker for erythroid-specific cells (Figure 5-5A). The 
CD45+CD34-CD36+ triple selection provided a well-defined erythroid lineage 
committed cell population for following direct reprogramming assay. 
To functionally characterize sorted cells, I seeded 5000 cells to 
methylcellulose media for colony forming cell (CFC) assay with 3 repeats. All 
colony forming units (CFUs) were counted on day 14 and revealed the majority of 
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BFU-Es and CFU-Es (Figure5-5B, C). Taken together, these data proved an 
erythroid-lineage committed blood cell population raised from CB MNCs.    
   
Generation of Cells with HSPC Traits via Retroviral Vector-Mediated 
Dedifferentiation  
The sorted cells were subject to a polycistronic retroviral vector infection that 
expresses OCT4, SOX2, KLF4, c-MYC and GFP genes (Figure 5-6A). GFP 
enabled tracking of transgene expression during the reprogramming process 
(Zhang et al., 2011). In parallel, I also infected cells with a retroviral vector (Park 
et al., 2008) or a lentiviral vector expressing single OCT4 gene. A mock vector 
that expressed only GFP was used as an efficiency control.  
Cells post-infection were plated to three distinct culture conditions for 
variant purposes. A portion of cells seeded on MEFs in the presence of NaB 
were for iPSC generation to monitor the quality of infection and cells. Some cells 
were cultured in serum- and feeder-free media (SFM). The remaining cells were 
co-cultured with OP9 stromal cells in serum-containing media. A combination of 
cytokines SCF, Flt3, TPO and IL-3 that favors the propagation of HSPCs were 
supplied to the latter two groups from day 3 post-infection throughout the 
experiment (Figure 5-6B).  
Colonies with iPSC-like morphology were first observed between day 8 to 
day 12 in the control group, indicating the success of reprogramming. TRA-1-60 
live staining also confirmed the genuineness of iPSCs (data no shown). Cells 
post-infection began to grow in OP9 free and OP9 co-culture conditions from day 
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14. GFP+ cells can be observed under the fluorescent microscope, indicating 
successful infection (Figure 5-7). Interestingly, some cells under OP9 cell co-
culture displayed cobblestone morphology which could be a sign of HSPCs 
(reviewed by Bock, 1997) (Figure 5-7). In contrast, cells infected by GFP control 
vector did not show cobblestone phenotype (data not shown).  
Growing cells from each culture condition were harvested for CD34 and 
CD45 marker detection on day 14 post-infection. Strikingly, I can detect a small 
population acquiring the CD34 marker (Figure 5-8) and maintaining CD45 
expression in OP9-free and OP9 co-culture conditions. CD34 and CD45 double 
positive is usually an indication of HSPCs. This double positive population 
continued to increase only in OP9 co-culture condition (Figure 5-6B, 5-8). In 
contrast, CD34+CD45+ cells exhausted in the culture condition free of OP9. 
Prolonged culture showed these CD34+CD45+ cells can be kept for about 4-6 
weeks with steady proliferation in OP9 co-culture condition. 
To further analyze the property of growing cells, I harvest growing cells 
and sorted CD34+CD45+ cells for CFC assay. Total colonies were documented 
on day 14 (Figure 5-9A left). Interestingly, the sorted cells can generate various 
types of colonies such as CFU-E, CFU-G and CFU-M (Figure 5-9A right). This 
data revealed the CD34+CD45+ cells possess multi colony forming capability. 
Unexpectedly, CD34-CD45+ cell population can also form colony-forming 
progenitor cells, although with lower efficiency. Cells harvested from CFU study 
were subject to cytospin assay. Several blood cell types including macrophage, 
neutrophil-like cells and globin positive erythroblasts can be identified (Figure 5-
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10). Taken together, these data provided evidence that multi-potent blood 
progenitors can be generated from lineage committed blood cells.   
 
Discussion 
In this chapter, I asked the feasibility of directly reprogramming cord blood 
derived lineage committed cells. This novel strategy may help us to derive 
valuable HSPCs which can’t be expanded extensively in vitro or generated from 
PSCs. Based on the erythroid expansion culture condition described in chapter 2, 
I used expanded CB MNCs as the starting cell population. After infection of four 
iPSC-factors by retrovirus and cultured in the condition that favors the 
propagation of HSPCs, I observed a net growth of infected cells. Most strikingly, 
some of the growing cells displayed CD34 and CD45 markers which are often 
expressed in HSPCs. When CD34 and CD45 double positive were sorted for 
colony forming cell assay (CFC), multiple colonies were generated, 
demonstrating the in vitro differentiation capacity of reprogrammed cells. 
However, a thorough characterization such as in vivo functional studies and 
transplantation assays are required to verify this result. 
By analogy with Waddington’s epigenetic landscape, this result is similar 
to pushing differentiated cells uphill to a more immature state within the same 
valley (Figure 1-1, red outlined arrow), and can be depicted as dedifferentiation. 
Although dedifferentiation occurs naturally in living organism repair, special care 
should be taken in an attempt to do dedifferentiation in an artificial cell culture 
environment. First, there is still a chance that some cells capable of multiple-
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blood-lineage forming reside in the CD45+CD34-CD36+ population. It should be 
vigorously examined that these cells are very rare or close to zero. Second, since 
a full set of four iPSC-factors was used for the infection, it is possible that some 
cells may be fully reprogrammed to iPSCs or go through a transient pluripotent 
state and then re-differentiate to CD34+CD45+ cells. To prove it is not the case, 
a culture condition that is not permissive for iPSC generation should be 
considered. For example, adding inhibitors such as oleate synthesis inhibitor can 
be an option to reduce the chance of full reprogramming (Ben-David et al., 2013). 
It would be also necessary to monitor cells at variant stages to check if 
pluripotent cells are generated. Direct single-cell reprogramming accompanied 
with time-lapse assay can help to demonstrate the occurrence of dedifferentiation. 
Eventually, reducing the transgene number and using factors not related to 
pluripotency are preferred.    
I noticed that once CD34+CD45+ cells emerged, they can expand in the 
presence of OP9 stromal cells for 8-10 weeks but then gradually decrease. 
Maybe the current culture condition is not ideal and can’t support CD34+CD45+ 
cells to proliferate in a long term manner. Finding a better culture condition will be 
necessary and advance the result. Although this study is based on an 
assumption that lineage committed blood cells after four iPSC factor induction 
acquire a flexible epigenetic status, it is unknown whether current culture 
condition can induce authentic hematopoietic program to cells. Will other 
transgene combinations elicit direct reprogramming more efficiently? Are 
reprogrammed CD34+CD45+ cells bona fide HSPCs or just progenitor cells with 
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limited hematopoietic differentiation potential? I have shown these emerged 
CD34+CD45+ cells can give rise to various CFCs in vitro, indicating they have 
certain differentiation capacity. Whether these cells are capable of engrafting and 
repopulating to multiple lineage blood cells in immuno-deficient mice awaits more 
studies. Also the global gene expression analysis and epigenomic study can lend 
clues how they resemble authentic HSPCs. 
In the meanwhile, it is noteworthy that the retroviral vector confers 
continuous expression of four iPSC transgenes in reprogrammed CD34+45+ 
cells. The prolonged expression of transgenes may hamper hematopoietic 
differentiation. Thus, switching to inducible or transient- expression system for 
direct reprogramming will help to turn off transgene expression and allow 
reprogrammed cells to achieve full hematopoietic differentiation. 
In summary, the molecular and cellular data presented in the chapter 
showed multi potent blood progenitors can be derived from lineage committed 
blood cells via a direct reprogramming strategy. It provides the first evidence that 
it is possible to dedifferentiate blood cells to progenitor cells. In another study, it 
was shown a combined of transcription factors (TFs) Gata 2, Gfi1b, cFos and 
Etv6 can induce hemogenic program in mouse fibroblasts (Pereira et al., 2013). It 
will be interesting to test if human fibroblast can be converted to blood cells using 
the same combination or other factors. It is also important to compare whether 
the general TFs (OSKM) or a customized combination of TFs can generate blood 
progenitor cells that more closely resemble authentic HSPCs. The ultimate goal 
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Adapted from Efe et al., Nat. Cell. Biol., 2011
Figure 5-1. A model for direct reprogramming to alternative cell
fates. Yamanaka 4 iPSC-factor induction may erase epigenetic state and
bring somatic cells to a transient and plastic status. Providing ESC culture
condition will induce cells to iPSCs, while exposing cells with distinct
developmental cues or culture conditions may guide cells to specific
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Figure 5-2. A scheme to show the hypothesis that lineage
committed blood cells can be directly reprogrammed to more





























Figure 5-3. Human cord blood mononuclear cells (MNCs) under
erythroid expansion culture condition. (A) Growth curve. (B) Cell
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Figure 5-4. Characterization of expanded cells. Mononuclear cells
expanded in erythroid culture conditions for 7-10 days expressed the pan
-hematopoietic cell marker CD45 (99%) and the erythroblast markers
CD36 (98%) and CD235a (34%), but not the hematopoiet ic





































Figure 5-5. Selection of lineage committed blood cells for
the direct reprogramming assay. (A) CD45+CD36+ but CD34- cells
were sorted as a defined lineage-committed cell population and to
exclude potential HSPC contamination. (B) Sorted cells mostly gave
rise to erythroid colonies (CFU-E), confirming their erythroid lineage














Figure 5-6. Infection and culture of reprogrammed blood cells. (A)
Schematic representation of the poly-cistronic retroviral vector
expressing Yamanaka 4 iPSC factors and GFP (MIG4F; Zhang et al.,
2011). (B) After retroviral vector infection, cells were cultured in a HSPC
condition in the absence or presence of OP9 stromal cell co-culture.





Figure 5-7. Lineage committed mononuclear cells successfully
infected by the retroviral vector expressed GFP. Cobblestone-like
blood cells can be observed in the OP9 co-culture condition, yellow
arrows. Day 10 post-infection.
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Figure 5-8. FACS analysis of reprogrammed cells revealed a
emerged CD34+ and CD45+ population. Under the OP9 stromal cell co-
culture condition, a novel CD34+CD45+ cell population showed up about
2 weeks post-infection and continued to expand to day 25 and beyond.
Since the retroviral vector expresses 4 iPSC factors as well as GFP, co-
expression of GFP and CD34 indicates the 4 iPSC factors are important




































































Figure 5-9. Reprogrammed CD34+CD45+ cells showed multi-lineage
differentiation potential. (A) Emerged CD34+CD45+ cells were purified
and can form various colony-forming progenitor cells in the CFC assay.
(B) Unexpectedly, CD34-CD45+ cell population can also form colony








Figure 5-10. Differentiated colony-forming cells harvested from




Conclusions and Future Perspectives 
 
 
In this thesis work, I tried to reprogram blood cells and address some of 
key questions surrounding the generation of induced pluripotent stem cells 
(iPSCs). My findings may help bring us a little closer to the future application of 
these cells in cell therapy and regenerative medicine. 
Reprogramming to pluripotency is a lengthy and stochastic process with 
extremely low efficiency (Hanna et al., 2009). Identifying an ideal cell type for 
reprogramming will make iPSC derivation more feasible and significantly 
enhance the efficiency. Therefore I worked to find a cell type that is amenable for 
induction within minimal culture period and can be easily acquired. My 
colleagues in the Cheng lab and I examined the epigenetic profiles of blood cells 
with age matched fibroblast or ESCs and iPSCs, and found blood cells are closer 
to ESCs and iPSCs than fibroblasts. In addition, blood can be easily acquired 
and has become routine practice in hospitals with low risk. Therefore, I targeted 
blood cells as my starting population for reprogramming.  
Most of reprogramming methods depend on viral vectors to delivery 
transgenes, which makes virus-mediated integration and transgene reactivation 
risk factors for future usage of iPSCs. To achieve the goal of deriving high quality, 
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virus-free and integration-free iPSCs, I tested the novel EBNA1/OriP episomal 
vectors expressing 5-6 reprogramming factors which were solely plasmid-based. 
I demonstrated CB CD34+ cells can be easily reprogrammed. The EBNA1/OriP 
episomal vectors also can generate iPSCs from adult CD34+ cells. Inclusion of a 
second episomal vector Tg had significant effect on refractory cell types. 
I also devised a new technique to propagate mononuclear cells (MNCs) 
from either fetal or adult blood. Instead of expanding MNCs to the lymphoid 
lineage which may induce DNA rearrangement and lead to altered genome, I 
used culture conditions for erythroblast proliferation. The expanded cells showed 
rapid growth and displayed erythroblast phenotypes. Most importantly, these 
robustly proliferating cells from CB origin were very amenable for episomal 
vector-mediated reprogramming. The relative efficiency of cells from adult origin 
(peripheral or bone marrow blood cells) was low, but sufficient iPSC colonies can 
still be readily generated. Detailed studies like QPCR, Sothern blot and whole 
genome sequencing proved episomal vector-derived iPSCs are footprint-free 
with minimal mutations. Other complementary studies showed the resulting 
iPSCs can differentiate to multiple cell lineages. Therefore, my thesis research 
developed a highly practical method to derive footprint-free human iPSCs from 
few milliliter blood cells from adult PB MNCs. This method will accelerate the 
usage of iPSCs in both research and clinical applications.     
The ability to reprogram somatic cells from healthy or diseased donors 
makes it possible to generate iPSCs carrying disease-causing mutations for 
disease modeling and drug development. To date, many iPSC lines from patients 
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of neurological, cardiac, blood and other diseases have been reported (Wu and 
Hochedlinger, 2011; Bellin et al., 2012). Recent studies also suggest that 
disease-specific iPSCs after differentiating to relevant cell types display certain 
disease features (Ye et al., 2009; Ebert et al., 2009; Carvajal-Vergar et al., 2010). 
However, most of disease-specific iPSCs are created by viral vector infection. 
Viral vector insertion to variant loci can render reprogrammed cells a 
heterogeneous population. Thus, individual iPSC clones may have subtle 
differences for differentiation and disease-recapitulation potential. To solve this 
problem, a reprogramming method that won’t cause integration variation is 
preferred. For this part of study, I used our integration-free technology to derive 
disease-specific iPSCs from a patient with a HIF2α mutation. Sequencing data 
confirmed the resulting iPSC line carried the disease-initiating mutation. It will be 
interesting to test if this cell line shows any disease related phenotypes after 
differentiation. Such integration-free iPSC line should provide an unbiased 
comparison for disease recapitulation. So far most of studies only used rather 
few iPSC lines to reproduce disease phenotypes. In the future, larger sets of 
genetically matched iPSCs from one patient or multiple iPSC lines from individual 
patients are required to verify disease-specific iPSCs can recapitulate disease 
traits. 
I also addressed the question of how to engineer iPSCs to facilitate cell 
differentiation. Although great efforts have been invested to improve direct PSC 
differentiation to functionally mature cells of various lineages with capability for 
therapeutic transplantation, to date the results are largely unsuccessful. This 
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issue undoubtedly represents one of the major challenges in PSC application. 
Hematopoietic development is arguably the most characterized cellular 
differentiation system in mammals. In addition, hematopoietic lineage 
differentiation is among the easiest to generate from PSCs. Therefore, 
developing a reporter system capable of lineage tracing will be beneficial. I first 
transfected iPSC line with piggyBac transposon vectors expression GFP. Long 
term passage of this transgenic cell line affirmed the stable and intensive 
expression of GFP. This cell line will be appropriate for in vivo lineage tracing 
assay.  
Creation of an iPSC line with hematopoietic-specific GFP reporter gene 
will greatly assists us to trace hematopoietic lineage commitment as well as to 
study mechanisms governing blood differentiation. To this end, I constructed a 
piggyBac vector carrying fragments of WAS-promoter and RUNX1 enhancer to 
drive GFP. After transfecting to BC1 iPSC line, I showed undifferentiated iPSCs 
did not express GFP. Importantly, I found some CD45+ hematopoietic cells 
differentiated from this reporter cell line expressed GFP. Although not all CD45+ 
cells co-expressed GFP gene, almost every GFP+ cells acquires CD45+ signal. 
At this time point, it is unclear why the GFP expression is not homogeneous in 
CD45+ population. One possibility is that CD45+ cells are heterogeneous and 
only partial of them were regulated by WAS promoter and/or RUNX1 enhancer to 
display GFP expression. It would be interesting to examine the differentiation 
potential of GFP +/- population. In sum, I have shown the usefulness of WAS 
promoter/RUNX1 enhancer to specifically express GFP in iPSC-derived 
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hematopoietic cells. This reporter iPSC line may serve as an ideal tool to isolate 
early hematopoietic progenitor cells and screen molecules that can enhance 
hematopoiesis.  
In the last part of this thesis, I sought to reprogram blood cells to cells 
relevant for clinical application. Although iPSCs provide a potential platform for 
cell therapy, iPSC per se is not clinically relevant. A pretreatment is required to 
differentiate iPSCs into therapeutically meaningful cells before we transplant cells 
to patients. But current differentiation protocol can’t derive any therapeutic cells 
from iPSCs. 
Recent studies showed the standard Yamanaka four factors were used to 
convert cell somatic cells to multiple lineages (Efe et al., 2011; Kim et al., 2011; 
Szabo et al., 2010). The assumption of this approach is that the four factors may 
“unlock” original cell fate and bring cells to a temporally plastic state. Different 
developmental cues and culture conditions would coax cells to the desired 
lineage. Therefore, I asked if four iPSC-factors can not only reprogram blood 
cells to iPSCs but also convert to therapeutic useful cell types such as 
hematopoietic stem/progenitor cells (HSPCs). I used the culture condition to 
expand blood mononuclear cells (MNCs) to erythroblast lineage. The expanded 
cells remained pan-hematopoietic marker CD45 positive and exhibited 
erythroblast markers, demonstrating they were lineage committed blood cells. To 
have a defined starting cell population, I sorted cells displaying erythroblast 
marker CD36 and excluded common HSPC marker CD34.  
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After retroviral vector transfection, I cultured cells under conditions 
favoring HSPC expansion. I tested both OP9-free and OP9 stromal cell co-
culture conditions. Strikingly, transfected cells acquired CD34 marker 14 days 
after transfection. The coincident expression of CD34 and CD45 markers implied 
some cells may gain HSPCs traits. I next collected CD34 and CD45 double 
positive cells for CFC assay and found they can form colony forming units of 
variant types, an evidence of multi-lineage differentiation potential. Taken 
together, my data showed it is possible to directly reprogram lineage committed 
blood cells to progenitors using the four iPSC factors. This phenomenon is 
analogous to dedifferentiation in Waddington’s epigenetic landscape. 
 My results seemed promising for the proof-of-principle of dedifferentiation, 
but it also raises various questions. Is there HSPC contamination in the starting 
cell population? Although sorting CD36+CD34-CD45+ triple positive cells 
diminished the possibility of presumable HSPC contamination, clonal isolation of 
starting cells should be tested to rule out the possibility. Second, to define more 
rigorously the phenomenon of dedifferentiation, we need better prove iPSC 
generation is not involved in the process. Although the culture condition favors 
the HSPC expansion, it is also permissive for potential iPSC generation and 
generation of CD34+ cells from iPSCs. The time lapse assay may help to figure 
out if iPSC is one of intermediate during CD34- to CD34+ transition. Third, 
capability of long term culture and expansion of CD34+CD45+ remains a huge 
challenge. The limitation of keeping reprogrammed CD34+CD45+ cells in culture 
may hamper the further characterization. Lastly, it is crucial to do functional 
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characterization of these reprogrammed CD34+CD45+ cells. They could be just 
artificial product during cell culture without any biological meanings. On the other 
hand, it is also possible that the cellular reprogramming-mediated 
dedifferentiation could recapitulate the very early stage of hematopoiesis. And 
such CD34+CD45+ cells could highly resemble authentic HSPC and hold 
potential in clinical application. Thus, the global gene expression study and in 
vivo transplantation assay will help us to answer these questions. 
 
Future Perspectives 
The groundbreaking discovery of induced pluripotent stem cells (iPSCs) 
opens up a new era for future personalized cell replacement therapy (Figure 6-1). 
My studies tried to solve several bottlenecks. First, I created an efficient and safe 
method to generate footprint-free iPSCs from easily accessible blood, including 
neonatal and adult origins. I also demonstrated the feasibility of generating 
patient-specific iPSCs which can serve as an ideal model for disease modeling 
and drug screening. To extend to usage of iPSCs, I developed a reliable 
hematopoietic reporter system. Hopefully it can help us to develop a better 
culture technique to perform direct hematopoietic differentiation from PSCs. 
In addition to standard iPSC-involved route for cell replacement therapy, I 
created a new path that is to directly reprogram lineage committed blood cells to 
potential clinically useful cell types—HSPCs (Figure 6-1). If a patient’s disease 
does not result from genetic mutation and no need of gene correction, one day 
we may go through this shorten path and bypass the route of iPSC generation 
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and gene correction. My data could open a regime of dedifferentiation for future 
regenerative medicine application. In conclusion, the field of stem cell biology 
and regenerative medicine is rapidly growing, hopefully one day my research 














Figure 6-1. The paradigm of reprogramming cells for regenerative
medicine. The paradigm begins with collecting patients’ somatic cells
(such as blood or skin cells). If a patient’s cells contain disease-causing
genetic mutations, cells will be reprogrammed to iPSCs using non-
integrating reprogramming technique and the genetic mutations will be
corrected in the iPSC stage. Next, immune-matched disease-free iPSCs
will be differentiated to functional and transplantable cell types for
autologous cell therapy. In the situation where gene correction is not
required, the patient’s cells can be directly reprogrammed to clinically
useful and transplantable cell types for subsequent cell therapy and
bypass the generation of iPSCs.
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Materials and Methods 
Approvals of Using Human ESCs, iPSCs and Primary Cells from 
Anonymous Donors 
The experimental designs using human ESCs and iPSCs were approved by the 
Institutional Stem Cell Research Oversight (ISCRO) committee in the Johns 
Hopkins University. Use of anonymous human samples for laboratory research 
was approved by the Institutional Review Board. 
 
Constructions of Episomal Vectors 
All transgenes were cloned into the EBNA1/OriP-based pCEP4 episomal vector 
(Invitrogen). A single EBNA1/OriP vector expressing five mouse cDNAs Oct4, 
Sox2, Klf4, c-Myc and Lin28 that are linked by 2A sequences and under the 
control of the synthetic CAG promoter was constructed in the pCEP4 plasmid 
backbone, analogous to a piggyBac transposon plasmid we previously used 
(Mali et al., 2010). The cDNA for the SV40 large T antigen was PCR cloned and 
inserted into the pCEP4 plasmid backbone as we did previously into a lentiviral 
vector (Mali et al., 2008). The expression cassette for expressing p53-shRNA 
was obtained by digesting a fragment from a pSUPER-based vector, and was 
inserted into the pCEP4 plasmid. The pSUPER-shRNA plasmid was purchased 
from Addgene (Cambridge, MA). The Thomson/Yu three EBNA1/OriP plasmids 
used in the combination #6 were also purchased from Addgene and used in 




Primary Cells from Anonymous Donors 
Most of human primary hematopoietic mononuclear cells (MNCs) obtained from 
anonymous donors were collected and frozen at AllCells, LLC (Emeryville, CA), 
including human MNCs expressing a high-level of the CD34 surface marker 
(CD34+) from newborn cord blood (CB), adult bone marrow (BM) and peripheral 
blood (PB) after G-CSF mobilization. CD34+ cells were isolated at AllCells or in 
our lab by the CD34 MACS beads (Miltenyi, Auburn, CA), although CD34 
depleted MNCs also contain MNCs expressing a low-level CD34 surface 
expression. For selected CB and PB samples donated by the parents or patients 
via their doctors, we isolated MNCs using a standard protocol by Ficoll-Paque 
Plus (p=1.077) purchased from GE HealthCare Bio-Sciences AB (Uppsala, 
Sweden). 
 
Culture Media and Conditions for Expanding Human iPSCs, and 
Karyotyping 
The human ESCs and established iPSCs were maintained on a mitotically 
inactivated mouse embryonic fibroblast (MEF) feeder layer in 
KNOCKOUT/DMEM medium (Invitrogen) supplemented with 20% KNOCKOUT 
Serum Replacement (KSR) (Invitrogen), 2 mM L-glutamine (Invitrogen), 2 mM 
nonessential amino acids (Invitrogen), 1x antibiotic/antimycotic mix (Invitrogen), 
0.1 mM β-mercaptoethanol (Sigma), and 10 ng/ml basic fibroblast growth factor 
(bFGF). All cytokines were purchased from Peprotech (Rocky Hill, NJ) if not 
otherwise indicated. Karyotyping of human ESCs and iPSCs by G-banding (300-
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500 bands) was examined by a certified cyto-geneticist by the method previously 
described (Mali et al., 2008; Ye et al., 2009; Mali et al., 2010). 
 
Constructions of WAS-Promoter/ RUNX1-Enhancer Reporter Vector 
The replication-defective HIV-based lentiviral vector containing 170 bp promoter 
of WAS with GFP was kindly provided by Dr. Morrone (Leuci et al., 2009). The 
WAS-GFP fragment was PCR amplified in order to create new restriction enzyme 
cutting site KpnI at 5’ position and cloned to TOPO vector. Then the full WAS-
GFP fragment was cut by KpnI/XhoI from TOPO vector and inserted into an 
empty piggyBac vector. The RUNX1 enhance element was obtained by PCR 
amplification from human iPSCs with new created NheI/KpnI site and cloned to 
TOPO vector. Then the enhancer element was isolated from TOPO vector by 
NheI/KpnI and cloned to upstream of WAS-GFP fragment. 
 
Infection of BC1 iPSC Line with Hematopoietic Reporter Vector 
2 million BC1 iPSCs were re-suspended in 100 μl mESC nucleofection solution 
(Amaxa/Lonza) with 5 μg of WAS/RUNX1 reporter vector or 5ug CAG-GFP 
vector and 5 μg of transposase. We used nucleofector II machine with A-023 
program for one-time transfection of BC1 iPSCs. The transfected iPSCs were 
cultured on MEFs in human ESC medium for 2 days. From day 3, we used 1 
μg/ml puromycin to select transfected cells for consecutive 7 days. To isolate 
cells with high expression of CAG-GFP, growing cells after puromycin selection 
were subject to cell sorting and reseeded on MEF-coated plates with human ESC 
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media. Only individual clones stably express GFP were picked and expanded. To 
derive clonal hematopoietic reporter cell lines, various clones were picked up and 
subject to spin-EB hematopoietic differentiation to isolate the clone with high 
percentage of GFP expression.  
 
Human CD34+ Cell Culture and Priming for Reprogramming by Episomal 
Vector Transfection 
Frozen human CD34+ cells from CB, adult BM and PB after G-CSF mobilization 
were purchased from AllCells. After thawing, CD34+ cells were cultured for 4 to 5 
days under a serum-free medium (SFM): containing 50% IMDM with 50% Ham’s 
F12 (Invitrogen), synthetic lipids (Invitrogen), ITS supplement (insulin-transferrin- 
selenium and 5 mg/ml BSA), 50 ug/ml of ascorbic acid and 2 mM glutamine (all 
from Sigma). The SFM is further supplemented with cytokines: SCF (100 ng/ml), 
Flt3 (100 ng/ml), human TPO (20 ng/ml) and IL-3 (10 ng/ml) for expanding 
CD34+ cells, similar to what we previously described (Ye et al., 2009). For 
reprogramming with EBNA1/OriP-containing episomal vectors, single or 
combinations of plasmids (up to 10 μg total) were co-transfected into 1-2X106 
human CD34+ cells via nucleofection (human CD34 cell solution [Nucleofector 
Kit VPA-1003] with the U-008 program, Amaxa/Lonza). Transfected CD34+ cells 
were cultured in one well of a 12-well plate in the same medium and cytokines for 
another 2 days. Subsequently, transfected cells were transferred to 3 to 6 wells 
of MEF-coated 12-well plates and cultured in MEF medium (DMEM + 10% FBS). 
Plates with seeded cells were spun at 500 rpm for 30 min at room temperature to 
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help cells attach to MEF-coated plates. The next day (day 3), the MEF medium 
was replaced with the ESC medium. Small organic molecules that enhance 
reprogramming such as sodium butyrate (NaB, 0.25 mM) and Valproic Acid 
(VPA, 0.5 mM) were also added at this time when indicated. The ESC culture 
medium was exchanged every 3 other day. Starting day 9 post-transfection, MEF 
conditioned medium (CM) was used to sustain the development of colonies. 
Colonies with morphology similar to iPSC colonies were readily visible on day 6 
to 10 post-transfection of CB CD34+ cells, and on day 10 to 14 post-transfection 
of adult BM and PB CD34+ cells. 
 
Human MNC Culture and Priming for Reprogramming by Episomal Vector 
Transfection 
After thawing, frozen MNCs from CB and PB were cultured in the SFM 
supplemented with the following cytokines and a hormone: SCF (50 ng/ml), IL-3 
(10 ng/ml), EPO (2 U/ml, R&D Systems), IGF-1 (40 ng/ml), and dexamethasone 
(1 μM, Sigma). The media were replenished at day 3 and 6. By day 8-9 when an 
overt sign of cell division was observed, cells were harvested for nucleofection as 
well for various analyses. Approximately 5-fold cells were obtained for CB at day 
8 and 1.5-fold for PB MNC at day 9. After optimizing nucleofection of the cultured 
MNCs to achieve maximal cell survival and gene transfer, we settled down with 
the human CD34 cell solution but with the T-016 program for one-time 
transfection of 2x106 cultured cells with 10 μg plasmid DNA. The transfected 
MNCs were cultured in the MNC medium with the same cytokines for 2 days and 
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then further reprogrammed on MEF feeder cells as described above with cultured 
CD34+ cells (Ye et al., 2009). The cultured human PB and CB MNCs for 8-9 
days were also analyzed by standard hematopoietic assays, in comparisons with 
newly thawed stock of the same types or after one-day culture. They were 
analyzed by flow cytometric analysis with a panel of monoclonal antibodies and 
by colony-forming assays for myeloid- and erythroid progenitor cells (Ye et al., 
2009). The stained cells were analyzed using FACS Calibur flow cytometer and 
CellQuest software (Becton Dickinson Immunocytometry Systems, San Jose, CA) 
as we described previously (Ye et al., 
2009). 
 
TRA-1-60 Live Staining for Identifying Fully Reprogrammed Clones 
TRA-1-60 antibody (mouse IgM, used as 1:300 of MAB4360, Millipore) and 
Alexa555-conjugated antimouse IgM secondary antibody (1:500, Invitrogen) 
were diluted in ESC medium and added in combination into reprogramming cell 
culture plates. The cell culture plates with sizable ESC-like colonies were 
incubated in 37°C for 1 hour before medium was changed to fresh ESC medium 
or CM after one time wash. TRA-1-60 positive colonies were identified under an 
inverted fluorescence microscope, and can be picked up (within 1 day after 
staining) for further expansion and characterization. For quantifying 
reprogramming efficiency we counted numbers of TRA-1-60+, hESC-like 
colonies as well as TRA-1-60- colonies. The efficiency is plotted as numbers 
(mean +/- SEM) of TRA-1-60+ cells per unit of nucleofected cells after culture 
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and priming (106 for CD34+ cells and 2x106 for MNCs). When numbers of 
duplicates are sufficient (n≥9), we performed t-test for paired samples assuming 
a normal distribution and equal variances. P value of ≤0.05 is considered to be 
significant. 
 
Immuno-Staining of Undifferentiated iPSCs 
To characterize clones by immuno-staining of various markers, cultured human 
iPSCs were fixed by 4% paraformaldehyde in PBS for 15 min, followed by 
permeabilization (required for detecting intracellular antigens) by 0.1% Triton X-
100 for 15 min, then washed with PBS for 3 times. The fixed samples were 
incubated with the following primary antibodies for 2 hours at room temperature: 
anti-TRA-1-60 (1:300), anti- SSEA-4 (1:10, MC-813-70, mouse IgG, 
Developmental Studies Hybridoma Bank, Iowa City, IA), anti-NANOG (1:100, 1 
μg/ml, rabbit IgG, Peprotech), anti-OCT4 (1:100, sc-5279, mouse IgG, Santa 
Cruz Biotechnology). After a brief wash with PBS, Alexa555 conjugated goat 
anti-rabbit or anti-mouse secondary antibodies (1:500, Invitrogen) were used for 
one-hour incubation to visualize the cells together with DAPI nuclear staining. In 
order to visualize the alkaline phosphatase (AP) activity, iPSCs were fixed and 
stained with Sigma’s FAST BCIP/NBT (B5655, Sigma). The AP assay was 
performed as per the manufacturer instructions. 
 
Embryoid Body (EB) Formation, Differentiation and Immuno-staining 
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EBs were formed using differentiation medium similar to culture medium except 
withdrawing bFGF and replacing 20% KSR with 20% FBS. Human iPSCs (near 
confluent) from 2 wells of a 6-well plate were used for EB formation and cultured 
in one well of ultra-low attachment 6-well plate. After 8 days, EBs were 
transferred to gelatin-coated 24-well plates for additional 2-4 days of attachment. 
Immuno-staining of EBs is similar to that of human ESCs or conventional iPSCs, 
with the following primary antibodies used: mouse anti-βIII-tubulin (1:1000, 
Sigma), mouse anti-actin, smooth muscle isoform (1:500, CBL171, Millipore), 
rabbit anti-AFP (1:500, DAKO). Alexa555-conjugated goat anti-mouse or anti-
rabbit secondary antibodies (1:500, Invitrogen) were used for visualization. The 
slides were last counterstained with DAPI to show cell nuclei. 
 
Teratoma Formation Assay of Pluripotency 
The use of immuno-deficient mice for the teratoma formation assay was 
approved by the Animal Care and Use Committee at Johns Hopkins University. 
Approximately five million iPSCs were harvested by Collagenase IV (Sigma) 
digestion (from one plates of 6-well plates), washed with PBS and resuspended 
in 200 μL diluted (1:1) Matrigel solution (BD). Cells were injected intra-muscularly 
into Rag1-/-γc-/- mice or NOD/SCID/IL2RG(γc)-/- immuno-deficient mice with a 
further reduced level of natural killer cells. Teratomas were excised 5-10 weeks 
after injection (Ye et al., 2009; Mali et al., 2010; Mali et al., 2008). After 
sectioning, slides containing various regions of teratomas were stained by H&E. 
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Complex structures with various cell types were examined at both low and high 
magnitude. 
 
Genome-Wide SNP Assay to Assess Genome Integrity 
The Illumina’s Omni1_Quad BeadArray chip (Illumina) containing >106 
informative SNPs was used. The array analysis was performed by the Johns 
Hopkins SNP Center as part of Center for Inherited Disease Research (CIDR, 
www.cidr.org). Based on 1,140,419 SNPs identified and the results with 2 control 
(CIDR11993 and CIDR10860) genomic DNA samples that have been previously 
sequenced and included in each run, the Johns Hopkins SNP Center reported a 
0.27% genotyping error rate in this run, within the normal range. Genomic DNA 
(~2 μg) isolated by the Qiagen DNAeasy kit from CT5 and CTN4 iPSCs (p7) that 
are derived from CB CD34+ cells, and the CD34- cells of the original CB donor 
(AllCells, #100204) were analyzed.The dis-concordance rate between CT5 or 
CTN4 iPSCs and the CD34- CB cells is 0.02% or 0.04%, which is much lower 
than the basal error rate level. In comparison, the dis-concordance rates between 
the CD34- cells (or iPSCs) and unrelated CIDR11993 or CIDR10860 controls are 
~40%. Therefore, our data analysis suggest that CT5 or CTN4 iPSC genome 
DNA is essentially identical to the CD34- cells and no change is found based on 
the Omni1 SNP analysis. 
 




Total DNA (genomic and episomal) from cell extracts was isolated using the 
DNeasy® kit from Qiagen. Equal amounts of DNA (100 ng) isolated from naive 
cells (before nucleofection) were used as negative control while the transfected 
sample (harvested at day 2 post-transfection) were used a positive control for 
vector DNA detection by the 35-cycle PCR reaction. Three sets of primers used 
for detecting vector DNA (in either episomal or integrated form) are: EBNA1_D: 
5’-TTTAATACGATTGAGGGCGTCT-3’, EBNA1_U: 5’GGTTTTGAAGGATGCGA  
TTAAG-3’, Tg_F: 5’-GCCAGGTGGGTTAAAGGAGC-3’, Tg_R: 5’-GGTACTTATA 
GTGGCTGGGCTGT-3’; SK_F: CCATTAACGGCACACTGCCCCTGT and SK_R: 
AGGACGGGAGCAGAGCGTCGCTGA (Yusa et al. 2009). The latter two primers 
are located at the junction the mouse Sox2 and Klf4 genes in the C5 
reprogramming gene cassette, and unable to amplify human genomic DNA. 
Plasmid DNA, either pEB-Tg or pEB-C5, was used as a control template when 
appropriate, and diluted to amounts equivalent to 1, 0.2 or 0.04 copies per 
genome of 100 ng genomic DNA from naïve cells. The detection of the single-
copy cellular gene beta-actin in the genomic DNA was employed to normalize the 
amount of genomic or total DNA used for PCR. We also used Southern blot to 
detect vector DNA in isolated total DNA using a 445-bp EBNA1 specific probe. 
The probe was synthesized by PCR amplification using primers EBNA1-5’: 
CCCAGGAGTCCCAGTAGTCAGTC and EBNA1-3’: GGAATAGCA 
AGGGCAGTTCCTCG and the DIG-dUTP labeling kit (Roche) as previously 
described (Zou et al., 2009). 5μg of total DNA from controls and iPSC samples 
was digested by BamH I. The pEB-C5 DNA plasmid was also digested by BamH 
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I (single cut) and used as a positive control for detection of unique vector DNA 
sequence. Plasmid control DNA was diluted in amounts equivalent to 0.8, 8 and 
80 copies per genome in 5 μg genomic DNA used. For genomic DNA quality 
control of iPSC samples, we used an 848-bp HBB probe made by PCR using 
primers 5'-GACTGAGAAGAATTTGAAAGGCG and 5'- TCATCAATTCTG 
CCATAAATGG. The wild-type genomic DNA after Pme I/EcoR V digestion 
showed a single4.3-kb band detected by the HBB probe, as expected. Standard 
Southern blotting and chemi-luminescence detection with CSPD were performed 
following the instruction manuals of DIG High Prime DNA Labeling and Detection 
Starter Kit II (Roche). 
 
PCR Analysis to Confirm the Authentic Origins of iPSC Lines (DNA 
Fingerprinting) 
Genomic DNA isolated from various iPSC lines and their parental (or related) 
somatic cells types from the same donor was used for the PCR-based DNA 
fingerprinting assay. Two sets of primers purchased from Invitrogen) were used. 
Details have been described in our previous publication (Ye et al., 2009; Mali et 
al., 2010; Mali et al., 2008).  
 
Preparation and Concentration of Retro-Viruses for Direct Reprogramming  
Coating 15 cm dishes with 12 ml of 50 μg/ml poly-D-lysine (invitrogen) dissolved 
in PBS for a period of 1 hour. Wash twice with PBS and then dispense 8-10 
million 293T cells in standard DMEM (high glucose) + 10% FBS to a total volume 
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of 20 ml. The next day, add 36 μl of Lipofectamine (Invitrogen) to 1.2 ml of OPTI-
MEM-I and incubate for 5 min at room temperature in a 5 ml polystyrene tube. In 
parallel, mix 24 μg of total DNA (i.e. 3 μg of VSV.G, 6 μg of retro-gag/pol, and 15 
μg of retroviral vector) into 1.2 ml of OPTI-MEM-I in another 5 ml polystyrene 
tube. After 5 minutes, mix the DNA mixture with Lipofectamine and incubate for 
20 minutes at room temperature. In the meantime, changed to fresh media in the 
293T cultures using DMEM (with 1% FBS) to a total volume of 20 ml. Finally, add 
the DNA-lipid complexes drop wise onto the 293T cultures. Gently swirl the 
plates and shake back and forth and sideways to mix uniformly and place dishes 
in the incubator.  After 48 and 72 hours, harvested the supernatant from the 
plates and added fresh DMEM with 1% FBS to a total volume of 20 ml to the 
plates for another harvest later. To eliminate the 293 cell contamination, filter the 
supernatant using a 0.45-μm filter unit (sigma, Whatman). To concentrate viruses 
by 50-100 folds the Centricon (Plus-20, 20 ml from Millipore) with a cut-off 
100,000 NMWL is our method of choice. The filter filtration method also helps to 
reduce the free form of VSV.G proteins that are toxic to target cells. Fill the 
device with ~14 ml virus-containing media and spin down for 20 min at 3000 rpm 
at room temperature. Each device concentrates 14 ml to ~200 μl each time. 
Trash the flow through and refill the device with rest virus-containing media until 
exhausted. Using this procedure starting from a volume of ~40 ml of supernatant 
we typically concentrate down to about 400 μl. The final 400 μl concentrated 
virus from original 40 ml of virus-containing media is good to infect 600 thousand 
cells. We recommend the use of freshly made viruses for transduction, but if it is 
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not possible, we make small aliquots and store them at –80°C where it is stable 
for 3 months.  
 
Virus Infection for Direct Reprogramming  
6X105 expanded PBMNCs were re-suspended in 400 μl concentrated virus in 15-
ml conical tube and spin down for 2-3 hours at 2000 rpm at room temperature 
(the scale can be enlarged). After spin-infection, transfered onto retronectin 
(optional, Takara) coated 1 well of 12- or 24-well. Added 100 μl fresh SFM with 
cytokines and the final concentration should be SCF 100 ng/ml, IL-3 10 ng/ml, 
IGF-1 40 ng/ml, EPO 2U/ml, transferrin 100ng/ml, dexamethasone 1μM and 
polybrene 6 ng/ml. We define the day of virus infection as day 0. One day later, 
added half SFM with cytokines to reduce polybrene concentration to 4 μg/ml. On 
day 2, harvested all cells and mixed with 10 ml PBS and spun down for 5 min at 
200g at room temperature. Removed supernatant and resuspended cells in SFM 
or SFM + 10%FBS or OP9 co-culture medium. From day 2, the cytokines would 
be SCF 100 ng/ml, IL-3 10 ng/ml Flt3 100 ng/ml, TPO 20 ng/ml,  bFGF 10ng/ml. 
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